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CHAPTER 1 
 
Introduction 
1.1 DNA Polymerases. 
DNA polymerases are enzymes that replicate DNA and are vital to the overall function of 
all living organisms. The enzymes work to create two new identical strands of DNA from two 
parent strands of DNA. The DNA polymerase ‘reads’ an existing template strand of DNA and 
creates a new strand that complements the first strand. This works in a semi-conservative fashion 
where the two ‘parent’ strands of DNA are unwound and the two newly synthesized strands form 
separately with the complementary pair for each, giving two copies of double-stranded DNA with 
one ‘parent’ and one ‘daughter’ strand of DNA (1). This family of enzymes is highly proficient in 
respect to both its rate of catalysis, at least for the processive DNA polymerases, as well as its 
astonishing fidelity in preventing misinsertions in the replication of DNA (2). 
The catalytic function of DNA polymerases is to synthesize DNA from 
deoxyribonucleotides (Figure 1.1). The polymerase works by binding to the template strand of 
DNA that the new primer strand is synthesized against. After binding to the template strand, the 
polymerase binds the nucleotide that complements the base in the template strand. The base 
pairing combines cytosine with guanine and thymine with adenine through Watson-Crick base 
interactions. Once the correct deoxyribonucleotide is in the active site of the polymerase with the 
template strand, the enzyme adds the nucleotide to the primer strand by forming a new 
phosphodiester bond between the terminal 3´-hydroxyl group on the primer strand and the 5´-a-
phosphate on the deoxyribonucleotide. The deoxyribonucleotide is inserted onto the primer strand 
and pyrophosphate is released. The polymerase then shifts down to the next free template base 
and the catalytic cycle is repeated. All DNA polymerases work in the 5´ to 3´ direction for the 
insertion of nucleotides into the primer strand of DNA.  
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The one commonality of all DNA polymerases is their DNA synthesis catalytic domain. In 
addition to the catalytic domain, the sequence of each DNA polymerase codes for secondary 
functions such as exonuclease activity, binding motifs (PCNA binding), or regulatory purposes 
(ubiquitylation sites). The structure of the catalytic domain of a DNA polymerase is often 
compared to that of a right hand, complete with subdomains called the thumb, palm, and finger 
(3-6). The thumb subdomain is responsible for binding to the DNA substrate. The finger 
subdomain interacts with the incoming deoxynucleotide and plays a role in positioning it near the 
template strand of DNA. The finger domain is important for monitoring the interactions between 
the incoming nucleotide and the DNA template to insure correct nucleotide incorporation and the 
preservation of the sequence of DNA. The finger domain is also responsible for the major 
conformational change that the polymerase complex undergoes prior to the catalytic step (7). The 
palm subdomain contains the two magnesium ions that are required for catalytic function of the 
enzyme. The palm domain contains the catalytic residues of the polymerases that perform the 
chemistry of the phosphoryl transfer (8). 
 
1.2 Families of DNA Polymerases. 
There are multiple families of DNA polymerases in both prokaryotic and eukaryotic cells, 
including families A, B, C, D, X, Y, and RT (Table 1). Of these, Families A, B, X, Y, and RT are 
found in eukaryotic organisms and in humans. Humans have 17 known DNA polymerases, many 
with overlapping functions (9).  
Family B DNA polymerases include a, d, e, and z. Pols d and e are the two crucial DNA 
polymerases found in humans. These are responsible for the majority of all replication. Pol d 
performs DNA replication in the lagging strand of DNA synthesis, whereas Pol e advances 
replication in the leading strand of DNA synthesis. Both of these polymerases have high 
processivity and insert several nucleotides per second. Although these polymerases have similar  
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Figure 1.1 Catalytic Cycle for DNA Polymerases. Adapted from Choi et al. (10). 
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functions, however on different strands of DNA, loss of either polymerase d or e is embryonic 
lethal. While these polymerases are naturally very selective in incorporating the correct nucleotide 
during replication, they also have 3´-5´ exonuclease activity, which allows them to proofread its 
previous insertions in order to replace mis-inserted nucleotides from the newly synthesized DNA 
strand when the wrong nucleotide is inserted on the primer strand. This ability to replace the 
misinserted nucleotide alleviates the errors caused by these replicative polymerases and gives 
these polymerases quite low levels of misincorporation (~1 x 10-9) (11). As well, the loss of this 
exonuclease function has been shown to result in tumorigenesis in mice (12). Pol a is responsible 
for initiating DNA replication on both strands of DNA, where it forms a complex with DNA primase. 
DNA primase inserts a short RNA primer onto the DNA template to start the replication process. 
Pol a then switches to the DNA template and uses an RNA primer to replicate approximately 
twenty nucleotides before switching off to the Pols d and e (13). Pol z is a translesion DNA 
polymerase and is involved in the inserting deoxyribonucleotides opposite stalled DNA replication 
forks when Pols d and e are stalled. It is also one of two known DNA polymerases to localize and 
perform mitochondrial DNA replication and repair (14). Pol z is believed to have a role in recruiting 
other translesion DNA polymerases to the active site of stalled replication forks (15). 
DNA polymerases that belong to family A include polymerases g, q, and n. Polymerase g 
is the major mitochondrial DNA polymerase and is responsible for mitochondrial DNA replication 
(16,17). It also has a DNA repair function in the mitochondria alongside pol z and contains a 3´-
5´ exonuclease function similar to the B family polymerases. Pol q is a nuclear DNA polymerase 
involved in DNA repair and translesion DNA synthesis (18). One of its major functions is for the 
repair of double-strand DNA breaks through non-homologous end-joining (NHEJ) (19). Pol q is 
capable of bypassing various DNA lesions such as thymidine glycol DNA adducts and abasic 
sites (20). Its amino acid sequence is similar to other A family polymerases except that it does 
not have any exonuclease function, resulting in higher error rates that are similar to Y-family 
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translesion DNA polymerases (see below). Pol n is the last of the A family of polymerases. This 
enzyme also is capable of performing translesion DNA synthesis opposite thymidine glycol (21). 
As well, it has a role in DNA repair through homologous recombination and is suspected of being 
involved in the repair of DNA cross-link repair through the Fanconi anemia pathway (22).  
Family X DNA polymerases b, l, µ, and TdT are mainly responsible for DNA repair but 
also have some translesion replication activity (23). The most recognized polymerase in this 
family is pol b, which is well characterized for its role in base excision repair (BER) in the removal 
of alkylated and oxidized bases as well as abasic sites from DNA (24). Loss of pol b in animal 
studies was shown to be lethal and resulted in death immediately after birth (25). Both pols b and 
l have been shown to bypass the DNA adducts 8-oxoguanine and 2-hydroxyadenine. DNA 
polymerase l is distinct from most other DNA polymerases for its preferential utilization of 
manganese as its divalent metal ion compared to magnesium for other polymerases (26). Pol l 
also is considered to be involved in non-homologous end-joining (27,28). Pol µ associates with 
XRCC4 and DNA ligase IV, suggesting that it is involved in V(D)J recombination (29). Terminal 
deoxynucleotidyl transferase (TdT) is a specialized DNA polymerase that adds nucleotides in the 
variable regions of immunoglobulins during V(D)J recombination, and it does not have the 
traditional ability of a DNA polymerase to incorporate nucleotides opposite a template strand of 
DNA (30). 
The Y-family DNA polymerases are involved in performing translesion DNA synthesis 
(TLS). This family includes polymerases h, i, k, and REV1. Y-family DNA polymerases are 
capable of bypassing DNA lesions when the replicative DNA polymerases are stalled. The 
importance of this family in performing TLS is signified by the evolutionary history of these 
polymerases, which are found in budding yeast (REV1) and even have archaeal and bacterial 
ancestry (pol k orthologues Dpo4 and Pol IV). These polymerases characteristically have a 
significantly larger active site compared to the replicative DNA polymerases d and e, which allows  
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Table 1.1 The 17 Human DNA Polymerases and Their Functions. Adapted from van Loon et al. (9).  
DNA pol HUGO name Family Proposed functions 
α POLA B Nuclear DNA replication/Initiation and priming 
δ POLD1 B Nuclear DNA replication; DNA repair 
ε POLE1 B Nuclear DNA replication; DNA repair 
ζ POLZ B TLS 
Υ POLG A Mitochondrial DNA replication and repair 
θ POLQ A TLS, DNA repair (end-joining) 
ν POLN A TLS 
λ POLL X NHEJ; base excision repair; TLS 
β POLB X Base excision repair 
TdT TDT X NHEJ; diversity 
μ POLM X NHEJ; diversity 
η POLH Y TLS 
ι POLI Y TLS 
κ POLK Y TLS 
REV1 REV1 Y TLS 
Telomerase TERT RTd Telomere maintenance 
PrimPol PRIMPOL AEP DNA replication, replication fork repriming; TLS 
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the Y-family polymerases to tolerate the additional size of the DNA adduct and continue on with 
the DNA replication. Along with the X-family of polymerases, the Y-family enzymes do not contain 
exonuclease functionality.  
 
1.3 Features of Translesion DNA Polymerases. 
The general structural features of the catalytic domain for Y-family polymerases are similar 
for the replicative DNA polymerases (31). Although they have poor sequence conservation, both 
feature similar catalytic domains featuring the ‘right hand’ topology. The active site for the Y-family 
polymerases is ample to accommodate the adduct in the template strand of DNA, leaving the 
active site more solvent exposed compared to the replicative polymerases (32). The finger and 
thumb domains are shorter, causing fewer DNA connections with both the DNA and the incoming 
dNTP. These modifications are crucial for allowing TLS to occur but lead to a decrease in 
processivity and fidelity of the enzyme. Y-family DNA polymerases also contain a little finger 
domain that replicative polymerases lack (31,33). This domain is responsible for mediating the 
contact with the DNA lesion in the active site of the polymerase. Orientation of this little finger 
domain also is selective for the type of DNA lesion that the polymerase is capable of bypassing 
(33). 
Y-family DNA polymerases are activated during DNA replication when the replicative DNA 
synthesis machinery pauses. There are two known pathways by which TLS can become 
activated. The first canonical pathway is through the ubiquitination of proliferating cell nuclear 
antigen (PCNA) (Figure 1.2) (34). PCNA ubiquitination signals the replicative polymerase (d or e) 
to dissociate from the DNA and the subsequent recruitment of Y-family polymerases to bind to 
the replication fork. The polymerases are capable of bypassing the lesion on the template strand 
and incorporating a free nucleoside on the newly synthesized primer. After this incorporation, the 
TLS polymerase will extend the replication fork along for several bases before PCNA is 
deubiquitinated, thus ending TLS replication. The Y-family polymerase dissociates from the 
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replication fork, allowing the replicative polymerase to switch back onto the fork. The second 
pathway is independent of PCNA ubiquitination, utilizing interactions within the polymerase REV1 
to be recruited to stalled replication forks as described below (35,36). 
Humans contain four DNA polymerases specific for translesion DNA synthesis, and each 
of these enzymes performs replication opposite different types of DNA lesions (32). Pol h is best 
known for its bypass of cyclobutane pyrimidine dimer (CPD) lesions (37). These lesions are 
commonly the result of UV radiation from sunlight. One of the variants of the disease xeroderma 
pigmentosum is caused by the deficiency of DNA polymerase h, resulting in skin discoloration 
and melanoma (38). It has the ability to bypass various other bulky lesions, primarily in the major 
groove of DNA. Pol h is also known for causing chemotherapeutic resistance in patients treated 
with cisplatin and other related drugs (39-41). Pol k has been shown to be important in the bypass 
of the major cellular oxidation DNA lesion, 8-oxo-(7,8-dihydro)guanine, as well as other common 
DNA lesions such as thymidine glycol and benzo[a]pyrene (42-46). The active site configuration 
of pol k allows it to perform TLS opposite bulky minor groove adducts, namely N2-guanine and 
N3-adenine adducts. Pol k has also been implicated for being involved in a number of DNA repair 
mechanisms including UV irradiation and the repair of DNA interstrand crosslinks through an 
involvement in the nucleotide excision repair (NER) pathway (47-49). Pol i is a unique DNA 
polymerase for a number of reasons. First, it uses Hoogsteen base pairing for inserting 
nucleotides into the DNA primer instead of normal Watson-Crick base pairing (50). This causes 
pol i to have a lower fidelity in incorporating the correct nucleotide compared to other Y-family 
and other DNA polymerases, especially for incorporation opposite dT. Magnesium is the 
canonical metal in the active site of DNA polymerases, but pol i has also been shown to be more 
active in the presence of manganese (51,52). DNA replication performed by pol i is distributive; 
the enzyme will incorporate one nucleotide onto the primer and then dissociate from the DNA 
(53,54). Longer incubations with the enzyme with replication forks will result the incorporation of 
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only a few nucleotides, while the other Y-family polymerases will continue on and incorporate 
several nucleotides. REV1 is not particularly known for its activity as a DNA polymerase. Its ability 
is restricted to the insertion of deoxycytidine opposite guanines in undamaged DNA as well in the 
bypass of bulky N2-G adducts (55-58). REV1 is mainly used as a scaffolding protein to recruit 
other Y-family DNA polymerases to the stalled replication fork (35,36). The other human Y-family 
DNA polymerases each contain a REV1-interacting region (RIR) motif that binds to REV1 (59-
61). This interaction is believed to crucial for the non-canonical mechanism for the recruitment of 
translesion polymerases for TLS. REV1 is also known to associate with pol z and is believed to 
be involved in the scaffolding for other DNA repair pathways (62).  
While the ability to resume stalled replication forks is advantageous to the cell to prevent 
long strands of single-stranded DNA, one major disadvantage of TLS DNA polymerases is that 
they are prone to causing misinsertions in DNA. This defect is caused in part by the lack of 
exonuclease function of the Y-family DNA polymerases, which replicative polymerases use to 
remove misinserted nucleotides and drastically reduce the mutation frequency for the replication 
cycle. The larger active sites of the Y-family DNA polymerases are vital to allow the enzymes to 
replicate past DNA lesions, but the larger active site also infringes on the proofreading ability of 
the enzymes. Y-family DNA polymerases perform TLS with greater fidelity compared to the 
replicative polymerases, but this misincorporation rate is considerably higher compared to 
replicative polymerases opposite undamaged DNA, and the Y-family DNA polymerases are also 
less stringent for the normal incorporation of nucleotides opposite undamaged DNA. The Y-family 
DNA polymerases can also be detrimental during certain chemotherapeutic treatments, permitting 
the cell to survive the damage caused by the drug instead of undergoing programed cell death. 
This phenomenon has been widely studied in the case of cisplatin, and the resistance that is 
caused by pol h. This information has led to the development of potential chemotherapeutics to 
also target these polymerases.  
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Figure 1.2 Mechanism for Translesion DNA synthesis. Adapted from Sale et al (63).  
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1.4 Chemical Carcinogens. 
Chemical carcinogens are substances that can act as genotoxins and damage DNA, 
creating alterations to the genetic code (Figure 1.3). While causing dangerous effects in cells, 
carcinogens are not necessarily immediately toxic to the cell. Therefore, their effects can manifest 
for extended periods of time before afflicting the cell. These lesions can lead to a variety of severe 
diseases such as neurodegenerative disorders and cancer. Chemical carcinogens come from a 
wide array of sources. They can be formed naturally in various species such as aflatoxin B1 from 
Aspergillus flavus as well as be found in various environments (arsenic). Carcinogens can also 
be man-made products, such as the nitrogen mustards and cisplatin that are used as 
chemotherapeutic agents. Carcinogens are also commonly found in the byproducts of combustion 
reactions such as industrial and tobacco smoke, byproducts of cooking of food, and fuel exhaust 
(formaldehyde, benzo[a]pyrene, nitrosamines, and 1,3-butadiene).  
Many chemical carcinogens work by adducting to the DNA (Figure 1.4). This adduction, 
or formation of DNA adducts, can cause negative effects numerous ways, based on the nature 
and characteristics of the DNA adduct. Bulky DNA adducts can alter the overall structure of DNA, 
thus changing the pattern of DNA binding proteins and disrupting signaling events on nearby DNA 
(64,65). Bulky DNA adducts can also block nuclear machinery from progressing alongside DNA 
(64). This disruption can affect processes such as DNA replication and RNA transcription, 
triggering long stretches of single strand DNA that is prone to breakages. Other DNA adducts 
localize inside of the DNA double helix and act as DNA intercalators (66). Intercalators position 
between the stacked DNA bases and often cause a kink or disruption in the DNA stacking 
interactions of the double helix. The disruption of the stacking interactions can also interfere with 
in the overall tertiary structure of DNA and block nuclear processes similarly to bulky DNA 
adducts. These types of adducts normally directly cause DNA damage due to the formation of 
DNA breaks, which can lead to DNA mutations and cancer. Smaller DNA adducts do not disrupt 
the cell until they are encountered by replication and transcription machinery. Depending on the 
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location of the modification, an adduct can disrupt the normal Watson-Crick base pairing of the 
DNA and cause a misinsertion to occur. If DNA repair proteins do not remove the adduct or the 
mispaired base, the misinsertion will remain in the DNA strand and become a DNA mutation. 
Although there is a wide array of DNA adducts, our cells have numerous ways to identify 
and correct DNA damage. Cellular antioxidants, such as glutathione, are utilized to sequester 
various reactive oxygen species and prevent their reaction with DNA (67). Direct repair proteins 
such as O6-alkylguanine DNA alkyltransferase (AGT) and AlkB directly remove DNA adducts to 
repair the original DNA base (68). Other repair mechanisms such as base-excision repair (BER), 
nucleotide excision repair (NER), and mismatch repair use enzymes to remove the DNA 
surrounding the damage before replacing it with new correctly synthesized DNA (69).  
 
1.5 Halogenated Hydrocarbons. 
 One class of chemical carcinogens consists of halogenated hydrocarbons. These are 
carbon molecules linked to one or more halogens (fluorine, chlorine, bromine, or iodine). 
Halogenated hydrocarbons are broadly used commercially and industrially as organic solvents, 
refrigerants, and propellants and in the generation of plastics and other polymers. Although these 
are widely used and are commercially important, there are some toxic effects of this class of 
molecules, dating back one hundred years to the use of mustard gases as chemical warfare 
agents in World War I. Chlorofluorocarbons were extensively used until their role in the depletion 
of the ozone was discovered. Many halogenated hydrocarbons are also alkylating agents, causing 
the transfer of an alkyl group from the halogenated hydrocarbon to nucleophilic groups such as 
thiols and amines on other compounds (70). This can have severe medical ramifications in that 
these alkylation reactions can occur with various biological molecules, and their roles in alkylating 
DNA defines some as chemical carcinogens (71,72). The alkylation of DNA can cause the 
disruption of nuclear processes such as DNA replication and RNA transcription, which can initiate 
tumors in  
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Figure 1.3 Mechanism of Action for Chemical Carcinogens. Adapted from Oliveira et al. (73). 
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Figure 1.4 Types of DNA Damage and Repair. Adapted from Morita et al. (74). 
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an organism. Their ability to alkylate DNA also gave rise to their use as chemotherapeutic agents 
to treat cancers as well (75). 
Historically, 1,2-dibromoethane (DBE, ethylene dibromide) has been used as an anti-
knock additive in leaded gasoline and also has had uses as a pesticide in soil and in the organic 
synthesis of various compounds, e.g. vinyl bromide. Annual production of DBE was >330 million 
pounds in the United States during the 1970s and has since rapidly declined, due to its health 
risks and ensuing regulations, to 1-10 million pounds per year by the end of the 20th century. DBE 
is a known carcinogen and had the highest hazard score for carcinogens in the Human 
Exposure/Rodent Potency Index prior to changes in the restrictions on the compound (76). DBE 
causes tumors in rats and mice in several different tissues, including the nasal cavity, blood 
vessels, skin, lung, kidney, and liver (77-80).  
DBE is detrimental because it is a bis-electrophile. The presence of two bromine atoms in 
the molecule allows it to undergo two nucleophilic substitution reactions, enabling the molecule 
to interact and become covalently bound to two different entities. This gives DBE the ability to 
crosslink two biomolecules to each other, including two proteins, two strands of nucleic acids, or 
a protein to a nucleic acid.  
 
1.6 DNA-Protein Crosslinks. 
When a protein becomes covalently bound to DNA through a crosslinking agent such as 
DBE, this process can cause severely detrimental effects to the cell including cytotoxicity and 
DNA mutations. DNA-protein crosslinks (DPCs) can comprise very bulky proteins that can alter 
the three-dimensional folding of DNA in the nucleus by affecting the ability of the DNA supercoiling 
as well as its interactions with the DNA histones, indirectly leading to alteration of DNA synthesis 
initiation and transcription initiation of RNA (81). In addition, DPCs can directly block the nuclear 
processes of DNA replication and RNA transcription (82-84). Both DNA and RNA polymerases 
contain narrow active sites to ensure high fidelity. Both of these enzyme classes are not 
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structurally designed to accommodate a protein covalently bound to the coding strand of DNA 
and consequently become blocked, which can cause detrimental effects to the cell by means of 
DNA replication stalling, single- and double-strand DNA breaks, and prevention of protein 
synthesis.  
A few studies have looked at the peptides and proteins that can become bound to DNA in 
DPCs (85-87). The first peptide found to be crosslinked was glutathione (GSH), which as 
described above is crucial for the removal of reactive electrophiles from the cell (88,89). Its 
mechanism for action uses GSH S-transferase (GST) to conjugate the protein to an electrophile 
through its reactive cysteine thiol, thus sequestering it from reacting with DNA (Figure 1.5). 
However, in the presence of a bis-electrophile like DBE, the second electrophile is still present 
after the conjugation to the first bromine to GSH. In the case of DBE, the second bromine can 
then react with the sulfur moiety of GSH via anchimeric assistance and form an episulfonium ion 
(89). This three-member ring is quite unstable due to the steric hinderance of the cyclic bonds. 
This process allows the cyclic group to react rather easily and was found to react with DNA. This 
paradoxically makes GSH part of the DNA adduct instead of preventing the electrophile from 
reacting with DNA. 
The same phenomenon has been characterized with the repair protein AGT. AGT utilizes 
its active site cysteine to find sites of DNA damage on the O6 position of guanine. Once it finds 
an adduct on this site, the cysteine reacts with the alkyl lesion on the guanine base and adducts 
it to the protein, thus signaling the protein for degradation. However, the bis-electrophile DBE will 
react with the active site cysteine sulfur atom of AGT (Cys-145) and form a highly reactive 
episulfonium ion, based on the results of work done with GSH (90). This episulfonium (also called 
thiiranium) ion then reacts with DNA to form a DPC at various sites on the DNA bases (92). The 
lesion has been found to occur at numerous sites on DNA and can cause significant detrimental 
effects to the cell, including cytotoxicity and an increase in DNA mutations (91,93).  
  17 
 
Figure 1.5 Mechanism of Formation of DNA-Protein Crosslink from Glutathione and 
Dibromoethane. Adapted from Cmarik et al. (99). 
  
GSH    + Br Br GST GS
Br GS
N
N
NH
N
N
N
N
NH2N
HN
O
GS
SG
dR
dR
N
N
NH2N
N
O
dR
GS
N
N
NN
H
HN
O
dR
GS
  18 
Broader studies have utilized proteomics to search for other proteins that can form DPCs 
via crosslinking agents such as BDE (86,87). These results show hundreds of proteins of varying 
cellular function and localization (Figure 1.6). Only two other proteins (histone H2b and 
glyceraldehyde 3-phosphate dehydrogenase) have been studied to test the effects of their 
crosslink (94,95). Peculiarly, neither of these proteins caused an increase in the number of cellular 
mutations in the cells treated (Figure 1.7). This leads to the hypothesis that only a select number 
of proteins will form DPCs with detrimental effects. The reason for why these proteins have 
detrimental effects and others do not is still unknown.  
 
1.7 Repair of DNA-Protein Crosslinks. 
DNA-protein crosslinks can be repaired in multiple ways. Select DPCs can be directly 
removed by the tyrosyl-DNA phosphodiesterase family of enzymes (TDP1 and TDP2). These 
enzymes can repair crosslinks that are formed through a linkage between the DNA 
phosphodiester backbone and tyrosine amino acids (96). This repair pathway is used for the 
removal of DNA topoisomerase crosslinks that can become trapped when cleaving either one or 
both strands of DNA to resolve torsion in the winding of the DNA helical structure. TDP1 resolves 
topoisomerase 1 crosslinks that form single-strand breaks. The result of the hydrolysis of the 
phosphotyrosyl bond formed by topoisomerase 1 is handled by single-stranded break repair 
enzymes PNPK, PARP1, XRCC1, and LIG3 to process and to fill in the gap on the DNA (97). 
TDP2 resolves crosslinks formed by topoisomerase 2, which normally forms double-stranded 
DNA breaks to relieve the helical stress on DNA (98). These double-stranded breaks are repaired 
by either of the canonical pathways, homologous recombination or non-homologous end joining. 
Unlike TDP1, TDP2 is unable to gain access to the phosphotyrosyl bond of topoisomerase 2 and 
requires proteolytic degradation of the topoisomerase 2 prior to repair. 
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Another mechanism for the removal of DPCs is through nuclease-dependent repair. This 
type of repair is dependent on the degradation of the DNA that surrounds the crosslinked protein. 
This system requires repair proteins to remove the damaged DNA. Endonucleases cleave both  
strands of DNA by the crosslink, leaving a double strand DNA break. This can result in the 
recruitment of repair proteins that are involved in homologous recombination (HR). HR utilizes the 
second copy of DNA to repair the double-stranded DNA break and prevent the loss of the genetic 
information that was coded in the lost sequence of DNA. This process can proceed in one of two 
pathways. The first pathway results in the crossing over of the second copy of DNA into the first 
copy prior to replication, resulting in Holiday junctions. The subsequent pathway uses the second 
copy of DNA only as a template to fill in one strand of the DNA, then using that strand as the 
template for the second strand of DNA. This repair pathway, while cumbersome, is a preferred 
pathway for cells to repair double-stranded breaks because it restores the DNA without losing any 
genetic information. The other process for the repair of double-stranded breaks is NHEJ. NHEJ 
does not utilize the second copy of DNA but instead cleans the termini of the DNA prior to ligating 
the broken ends together. This mechanism can be mutagenic due to the loss of the DNA that is 
lost during the double strand break or during the processing by the NHEJ proteins to remove DNA 
bases prior to ligation. 
Double-stranded DNA breaks can also occur without removing the DPC but rather leaving 
it on the terminus of cleaved DNA. This type of DPC can be removed by the MRN complex, 
consisting of meiotic recombination 11 (MRE11), RAD50, and Nijmegan breakage syndrome 
protein 1 (NBS1). These enzymes will cut the DNA prior to the DPC break that is then repaired 
by either HR or NHEJ. A simpler repair mechanism is NER. This strategy recognizes bulky DNA 
lesions and excises only the damaged strand of DNA and leaves the undamaged strand alone, 
thus causing only a single-stranded DNA break that are significantly less harmful compared to 
double-stranded DNA breaks. Once the damaged strand is excised from DNA, polymerases are 
recruited to synthesize the complementary sequence from the undamaged single-stranded DNA.  
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Figure 1.6 Distribution and Function of Proteins Found in DNA-Protein Crosslinks. Adapted 
from Ming et al. (87). 
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Figure 1.7 Co-treatment of the Crosslinking Agent Diexpoxybutane with Histone H2b and GAPDH 
Does Not Increase Mutation Frequency. Bacteria treated with the crosslinking agent, 
diepoxybutane, while expressing either histone H2b (top) or GADPH (bottom) do not incur the 
significant increase in DNA mutations as compared to when expressing AGT in the cells. Adapted 
from Loecken et al. and Loecken et al. (94,95). 
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One major limitation to the NER pathway is that it is unable to remove larger proteins (larger than 
10 kDa) from DNA (100,101). Therefore, nuclear proteases are required to degrade the adducted 
protein on the DNA strand to a small enough size to allow NER to proceed.  
One major challenge that can occur with DPCs is their effect when encountering a DNA 
replication fork. While one of the pathways outlined above could repair the lesion, these can be 
time-consuming or would not be accessible during replication. Therefore, it has been speculated 
that DPCs could be bypassed by the Y-family DNA polymerases during TLS. This would bypass 
the lesion, preventing a blocked replication fork and a stretch of single strand DNA. However, no 
TLS polymerase is capable of accommodating the great size of a crosslinked protein to allow 
direct bypass of the lesion. Therefore, for this pathway to work, a nuclear protease would be 
required to degrade the protein to a smaller (<10 kDa) peptide prior to TLS. 
 
1.8 Degradation of DNA-Protein Crosslinks. 
As described above, there has been evidence for the requirement of a nuclear protease 
to degrade DPCs for numerous DPC repair pathways as well as for potential TLS of the lesion 
(Figure 1.8). Without such a protease, DPCs would block cellular processes such as DNA 
synthesis and DNA repair, leading to severe DNA damage and even cell death. Because of this, 
there has been a recent interest in determining the identity and functionality of such a protease.  
Recently the protease Wss1 was found in yeast and shown to degrade DPCs (102). Yeast 
cells that lacked the Wss1 protease accumulated DPCs after crosslinking treatment, leading to 
substantial chromosomal rearrangements and cell death. Purified Wss1 can cleave DNA binding 
proteins such as topoisomerases and histones but would not cleave non-DNA binding proteins, 
e.g. bovine serum albumin or GST, even in the presence of DNA. This was the first evidence of 
a nuclear protease that could degrade DPCs for either further repair processes or translesion 
DNA synthesis.  
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A human homologue of Wss1, SPRTN (Spartan, DVC1), was first discovered in 2012. The 
name SPRTN is derived from the putative zinc metalloprotease domain SprT located in the N-
terminal part of the protein. However, it was first characterized by its C-terminal domain as a 
facilitator for p97 binding to stalled replication forks, and was thought to be involved in regulating 
DNA damage response (103). SPRTN is recruited to damaged DNA by ubiquitinated PCNA and 
RAD18, where it binds preferentially to ubiquitinated PCNA (104). It was also found to directly 
interact with DNA polymerases d and h, leading to speculation about a function in either up- or 
down-regulating TLS (105,106). Further studies identified germline mutations in SPRTN as a 
cause of Ruijs-Aalfs syndrome (RJALS), which is characterized by DNA instability, premature 
aging, and early-onset hepatocellular carcinoma (107). Complete knockout of SPRTN is 
embryonic lethal in mice, and knockout studies in cells showed incomplete DNA replication, 
formation of micronuclei and chromatin bridges, and eventually cell death (108), as well as 
sensitivity to UV irradiation and various chemical crosslinking agents (109,110). SPRTN 
hypomorphic mice accumulated topoisomerase DPCs in their livers (111). 
SPRTN contains 489 amino acids. The N-terminal side of the protein contains the putative 
zinc-dependent metalloprotease domain. Its C-terminal side contains regulatory and binding 
domains. The interaction domain for p97 (SHP domain) is located at residues 252-261. The PIP-
box for its interaction with PCNA is located at residues 325-332. Located at the very end of the 
protein, SPRTN contains recognition module for ubiquitin (453-475). It has also been identified 
that there is a DNA binding pocket located between the Sprt domain and the SHP domain.  
The role of SPRTN as a protease for degrading DPCs was reported in 2016 in by two 
different labs (110,112). Due to the effects of the cellular stress imposed when knocking down 
SPRTN and treating with crosslinking agents, it was speculated that SPRTN could have a role in 
the repair of crosslinks. Both research groups were able to show that SPRTN is a zinc-dependent 
metalloprotease and is dependent on DNA for its activity. They were able to show that SPRTN   
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Figure 1.8 Pathways for the Formation, Degradation, Bypass, and Repair of DPCs 
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will cleave both itself and other DNA binding proteins in the presence of DNA but does not have 
any activity in the absence of DNA nor on non-DNA binding proteins (even in the presence of 
DNA). It was shown that SPRTN cleavage is dependent on the N-terminal SprT domain and that 
it is still active without any of the C-terminal binding motifs after its DNA binding area. SPRTN 
also has high binding affinity to DNA, with a Kd value of 100 nM. Its affinity for binding DNA is 
similar whether the DNA is single- or double-stranded or in a splayed duplex DNA. Its cleavage 
was also determined to be metal dependent as shown by its inhibition by 1,10-phenanthroline, a 
metal chelator. Point mutations of key residues in the SprT domain have also shown a loss in 
activity, notably E112Q and Y117C. The activity of SPRTN in its auto-cleavage was shown to 
occur in trans, where one molecule of SPRTN can only degrade another molecule of SPRTN and 
not itself. 
Purified SPRTN can cleave topoisomerase, histones H2A, H2B, and H3, Fan1, HLTF, and 
Rad5. Interestingly, there have been conflicting results on the type of DNA required for this 
proteolysis. SPRTN autocleavage has been shown to occur in both ssDNA and dsDNA. However, 
the Boulton group concluded that SPRTN will only cleave other proteins in the presence of ssDNA 
but not dsDNA (112). Other groups including those of Ramadan and Haracska found that SPRTN 
will cleave these DNA binding proteins in either ssDNA or dsDNA (110,113).  
 
1.9 Research Aims 
The purpose of my dissertation is to understand the ability of Y-family DNA polymerases 
to bypass DPCs. Previous work had shown that crosslinks formed via adduction with GSH and 
AGT are both cytotoxic and mutagenic. My primary focus is to determine the mechanism for these 
adverse effects and to determine if the mutagenesis occurs due to TLS misinserting nucleotides 
opposite or nearby the site of the lesion. I am fascinated by the fact that these select adducts 
have harmful effects but that crosslinks formed with either GAPDH or histone H2b do not. Due to 
the fact that AGT is presumed to be too large a protein to be directly bypassed by any DNA 
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polymerase, another goal of this dissertation is to study the ability of the protease, SPRTN to 
degrade AGT protein crosslinks on DNA to allow for direct bypass by a translesion DNA 
polymerase. 
Detailed materials and methods for the research I performed is described in Chapter II. 
Chapter III describes the effects of GSH-crosslinks on the N6 position of adenosine. This 
lesion was identified on DNA and its relative quantitation compared to the other sites of adduction 
was calculated. A DNA oligonucleotide was synthesized containing a site-specific GSH crosslink 
on the N6 position of adenosine. Steady-state kinetics were performed to determine the changes 
in performance by various DNA polymerases as well as their misincorporation frequencies. LC-
MS DNA sequencing of the bypass products was also tested to identify frameshift mutations. 
Chapter IV describes the characterization of AGT-DNA crosslinks. DNA oligonucleotides 
were synthesized containing site-specific AGT peptide crosslinks. These oligonucleotides were 
then utilized for in vitro bypass assays and kinetic analysis. SPRTN protease was expressed and 
purified to degrade AGT-DNA crosslinks, which allowed translesion DNA synthesis to occur.  
Chapter V contains my concluding remarks, discussion, and future directions for this 
research. 
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CHAPTER 2 
 
Materials and Methods 
2.1 Materials 
2.1.1 Enzymes 
Human DNA Pol h, i, and k (catalytic core—hPolh: 1-432 amino acids, hPoli: 1-420 amino 
acids, hPol k: 19-526), Sulfolobus solfataricus DNA polymerase Dpo4, bacteriophage T7 DNA 
polymerase, and Escherichia coli Klenow fragment were expressed and purified as described 
previously (42,114-118). Uracil-DNA glycosylase (UDG) was purchased from New England 
Biolabs (Ipswich, MA). Alkaline phosphatase was purchased from Promega Corporation 
(Madison, WI). DNase I, Benzonase®, and phosphodiesterase I were purchased from Sigma 
Aldrich (St. Louis, MO). Tobacco etch virus (TEV) protease and the gene construct for SPRTN 
were purchased from Genscript (Piscataway, NJ).  
2.1.2 DNA Substrates 
6-Chloropurine deoxyribonucleoside was obtained from Alfa Aesar (Haverhill, MA). 
Unmodified oligonucleotides were purchased from Integrated DNA Technologies (Coralville, IA) 
and were HPLC-purified by the manufacturer. 6-Chloropurine phosphoramidite was obtained from 
Prof. Carmelo Rizzo (Vanderbilt University, Nashville, TN). Oligonucleotides containing a 6-
chloropurine were synthesized on a Perspective Biosystems model 8909 DNA synthesizer on a 
1-μmol scale using Expedite reagents (Glen Research, Sterling, VA), utilizing a standard synthetic 
protocol, and were purified by HPLC using a Phenomenex Alumina RP octadecylsilane (C18) 
column (250 mm ´ 4.6 mm, 5 μm). Buffers consisted of Mobile Phase A (0.10 M NH4HCO2) and 
Mobile Phase B (CH3CN). The following gradient program (v/v) was used with a flow rate of 1.5 
mL/min:  starting point 0% B, increased to 10% B over 15 minutes, then increased to 20% B at 
20 min, held at 20% B for 5 min, increased to 80% B for 3 minutes, held at 80% B for 4 minutes, 
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and re-equilibrated for 5 min at 0% B (all v/v). The UV detector was set at 240 nm. All other 
nucleotides used for replication assays or SPRTN assays were purchased from either Integrated 
DNA Technologies (Skokie, IL) or Midland Certified Reagent Company (Midland, TX).  
2.1.3 Other Materials 
Isopropyl-β-D-1-thiogalactopyranoside (IPTG) was purchased from Anatrace (Maumee, 
OH). GSH, N-(tert-butyloxycarbonyl) (BOC)-protected 2-bromoethylamine, 1-bromo-2-
chloroethane, Mesitylene sulfonyl chloride, and other chemical reagents were purchased from 
Sigma-Aldrich. Synthetic peptides from the AGT active site (PCH, LIPCHRV, and 
PVPILIPCHRVVSSS) were purchased from New England Peptides (Gardiner, MA), with the N-
terminus protected using an acetyl group and the C-terminus protected using an amide group. 
The pNIC-ZB expression vector was purchased from Addgene (Cambridge, MA). 
 
2.2 Methods 
2.2.1 Chemical Synthesis 
2.2.1.1 Synthesis of S-(2-Aminoethyl)GSH 
GSH (50 mg, 163 μmol) was dissolved in 10 mL of CH3OH along with 20 mg (0.86 mmol) 
of Na°. A solution of N-BOC-protected 2-bromoethylamine (72.2 mg, 322 μmol), in 5 mL CH3OH, 
was added dropwise. The reaction mixture was stirred for 24 h before quenching with 0.7 mL 
glacial CH3CO2H. The reaction product was dried under a stream of N2. The resulting white solid 
was redissolved in H2O before purification by HPLC (mobile phase A: 0.01% CH3CO2H in H2O, 
mobile phase B: 95% CH3CN in H2O with 0.01% CH3CO2H, all v/v) using a semi-preperative 
Beckman Ultrasphere RP octadecylsilane (C18) column (250 mm ´ 10 mm, 5 μm). The following 
gradient program (v/v) was used with a flow rate of 3 mL/min:  starting point 2% B, increased to 
10% B over five minutes, then increased to 30% B at 10 min, held at 30% B for 5 min, and re-
equilibrated for 5 min at 2% B (all v/v). The UV detector was set at 240 nm. The N-BOC-protected 
S-(2-aminoethyl)GSH was collected and its structure was confirmed by positive ion ESI-MS/MS. 
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The compound was then redissolved in a mixture of 2.5 mL of CH2Cl2 and 0.3 mL CF3CO2H and 
stirred for 1 h to remove the N-BOC. The reaction mixture was dried under a stream of N2 before 
repurification by HPLC using the same protocol as above. 
2.2.1.2 Synthesis of S-[2-(N6-Deoxyadenosinyl)ethyl]GSH  
S-(2-Aminoethyl)GSH (180 μmol) was dissolved in a mixture of dimethyl sulfoxide (DMSO) 
(225 μL) and N,N-diisopropylethylamine (DIPEA) (25 μL) and added to dry 6-chloropurine 
deoxyribonucleoside (1 μmol). Following the incubation at 60 °C for 24 h, the reaction mixture 
was purified by HPLC as shown above, identified by 1H-NMR (Figure A.1), and quantified by UV 
absorbance at 260 nm (119). 
2.2.1.3 Synthesis of S-[2-(N6-Deoxyadenosinyl)ethyl]GSH-Containing Oligonucleotide 
S-(2-Aminoethyl)GSH (750 nmol) was dissolved in a mixture of (CH3)2SO (100 μL) and 
DIPEA (25 μL) and added to a dry 6-chloropurine-containing oligonucleotide (5´-
TCTCXGTTTATGGACCACC-3´, where X is 6-chloropurine) (15 nmol) (Figure 2.1). Following 
incubation at 60 °C for 24 h, the reaction product was purified by 15% (w/v) polyacrylamide gel 
electrophoresis, visualized using a UV lamp (to locate bands), cut out of the gel, and extracted 
using a solution of 200 mM NaCl/1 mM EDTA (pH 8.0); the identity was confirmed by negative 
ion ESI-MS (Figure A.2). 
2.2.1.4 Alkylation of Calf Thymus DNA  
S-(2-Chloroethyl)GSH was synthesized by dissolving 0.5 g (1.6 mmol) of GSH in 12 mL 
of dry CH3OH in which 0.12 g of Na° had been dissolved (120). A solution of 2.3 g (16 mmol) of 
1-bromo-2-chloroethane in 12 mL of CH3OH was then added dropwise to the GSH solution and 
stirred for 1 h before quenching with 0.25 mL glacial CH3CO2H. The resulting precipitate (S-(2-
chloroethyl)GSH) was collected by centrifugation (2000 ´ g, 10 min). It was redissolved in 0.5 M 
Tris-HCl buffer (pH 7.7) containing 10% CH3OH (v/v) to a final concentration of 10, 50, or 250 mM 
and immediately added to a solution of calf thymus DNA (2 mg/mL) in the same buffer (final   
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Figure 2.1 Reaction Scheme for the Synthesis of S-[2-(N6-Deoxyadenosinyl)ethyl]GSH-
Containing Oligonucleotide 
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volume for the reaction was 250 μL). The reaction was incubated at 37 °C for 30 minutes. After 
the incubation the DNA was precipitated by the addition of 2.5 volumes of cold C2H5OH and 
digested using a combination of nucleases consisting of phosphodiesterase I from Crotalus 
adamanteus venom (0.02 units), bovine pancreatic DNase 1 (20 units), and calf intestinal alkaline 
phosphatase (5 units) at 37 °C for 24 h. The resulting solution was filtered through a Microcon 
10K Centrifugal filter before drying using centrifugal lyophilization. The samples were redissolved 
in 100 μL of running buffer (0.1% HCO2H in H2O, v/v) and analyzed by UPLC-MS. The solvents 
used were Mobile Phase A (0.1% HCO2H in H2O, v/v) and Mobile Phase B (0.1 % HCO2H in 95% 
CH3CN in H2O, v/v). The following gradient was used at 0.3 mL/min:  start at 0% B, hold for 5 min, 
increased to 30% B at 13 min, then increased to 95% B at 15 min, and maintained there for 2 min 
before re-equilibrating to 0% B at 19 min (all v/v). The temperature of the column was 40 °C. 
Product ion spectra were collected over the m/z range of 100-1000, and MS/MS fragmentation 
spectra were collected over the m/z range of 160-700. The MS conditions were as follows: 
capillary temperature, 350 °C; source voltage, 5 kV; capillary voltage, 13 V; tube lens voltage, 60 
V. MS fragmentation analysis was performed with a collision energy of 35%, m/z isolation width 
of 2, activation Q of 0.25, and an activation time of 30 ms. 
2.2.1.5 Synthesis of O-(Mesitylsulfonyl)hydroxylamine  
 Ethyl hydroxamate (23 mmol) was stirred in 9 mL of a 2:1 mixture of dimethylformamide 
(DMF) and triethylamine and cooled to 0 °C. Mesitylene sulfonyl chloride (23 mmol) was slowly 
added and stirred for an additional 15 min before diluting in 100 mL dichloromethane. The reaction 
product was washed ten times with H2O, and the organic layer was collected and dried using 
brine and MgSO4 before removing the solvent by vacuum. The reaction product was redissolved 
in 4 mL dioxane and cooled to 0 °C before adding 1.8 mL of 70% perchloric acid dropwise over 2 
min. The solution was stirred for an additional 2 min and transferred into 200 mL of chilled H2O 
prior to extracting with 100 mL diethyl either. The organic layer was neutralized and dried using 
KCO3 and filtered. The filtrate was concentrated and added to 150 mL of chilled hexane to 
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crystalize the product overnight at -20 °C. The O-(mesitylsulfonyl)hydroxylamine (MSH) crystals 
were collected, dried under vacuum, and stored at -20 °C. 
2.2.1.5 Synthesis of Dehydroalanine Peptides from AGT  
 Synthetic peptides from the active site of AGT (n = 3, 7, and 15 aa; 10 μmol) were 
dissolved in 200 μL H2O and treated with 2.1 equivalents of MSH and 10 equivalents of potassium 
carbonate dissolved in 200 μL DMF at 0 °C for 20 min to form dehydroalanine-containing peptides. 
Peptides were purified by HPLC using the same protocol as above. 
2.2.1.6 Synthesis of S-[2-(N6-Deoxyadenosinyl)ethyl]AGT Peptide-Containing Oligonucleotides 
 The 6-chloropurine-containing oligonucleotide (characterized above) (15 nmol) was 
incubated with cystamine dihydrochloride (5 μmol) in 100 μL of 150 mM DIPEA in H2O at 50 °C 
overnight. The reaction product was desalted and dried by lyophilization before resuspending it 
in 50 μL H2O. The oligonucleotide was further reduced using 1 mM of either DTT or TCEP in a 
solution containing 50 mM Na2PO4 (pH 8.0) and 100 mM NaCl at 50 °C for 30 min. The 
oligonucleotide was reacted with 250 nmol of the dehydroalanine-containing peptide at 37 °C for 
48 h. The product was desalted using a solid phase extraction column (Oasis HLB, Waters), and 
its identity was confirmed by negative ion ESI-MS.  
2.2.1.7 Synthesis of AGT Protein DNA Crosslink 
 The 6-chloropurine oligonucleotide (characterized above) (15 nmol) was incubated with 
propargylamine (5 μmol) in a mixture of 1 M DIPEA in dioxane (25 μL) and H2O (75 μL) at 55 °C 
for 24 h before desalting using a solid phase extraction column (Oasis HLB, Waters) and purifying 
by HPLC (Figure 2.2). The 12mer primer strand of DNA was then annealed to DNA in 50 mM 
HEPES (pH 7.4) with 50 mM NaCl at 95 °C for 5 min. The DNA duplex was modified using a 
copper-catalyzed azide-alkyne cycloaddition reaction for 4 h in the dark by the addition of 2 mM 
azide linker with an iodoacetamide attached to its terminus (Figure 2.2). The DNA duplex was 
then incubated with recombinant AGT for 3 h in the dark to allow the active site thiol of AGT to 
crosslink to the DNA duplex at the iodoacetamide position. The AGT crosslink was purified by   
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Figure 2.2 Synthesis scheme for AGT DNA crosslink. DNA oligonucleotide containing a 6-
chloropurine was treated with propargyl amine before annealing the primer strand of DNA. The 
crosslinking agent was then attached to the oligonucleotide utilizling click chemistry before 
reacting with the AGT protein.  
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FPLC using a Ni2+-nitrilotriacetic acid (NTA) or Co2+-NTA based IMAC column (GE Healthcare) 
and analyzed by gel electrophoresis and proteomic analysis.  
2.2.2 DNA Replication Studies 
6-Carboxyfluorescein (FAM)-Labeled Primer Extension and Steady-State Kinetic Assays. 
A 12-mer oligomer (FAM-5´-GGTGGTCCATAA-3´, for full primer extension in the presence of 
four dNTPs) and a 14-mer oligomer (FAM-5´-GGTGGTCCATAAAC-3´, for single base primer 
extension and steady-state kinetics in the presence of single dNTPs) were annealed to the 19-
mer oligomer template (5´-TCTCXGTTTATGGACCACC-3´, where X is dA or S-[2-(N6-
deoxyadenosinyl)ethyl]GSH). Primer extension was performed with 120 nM oligonucleotide 
complex in 50 mM Tris-HCl buffer (pH 7.5) containing 50 mM NaCl, 5 mM MgCl2, 500 μM dNTPs, 
2% (v/v) glycerol, 50 μg/mL bovine serum albumin (BSA), and 20 nM polymerase (with the 
exception of hPol ι, 40 nM) at 37 °C. Steady-state kinetics were performed under the same 
conditions except using polymerase concentrations from 1-40 nM, varying dNTP concentrations 
(0.1-500 μM), and incubation times from 5-30 min so that the maximum incorporation was < 20% 
of the substrate concentration. Reactions were quenched with 7 μL of 20 mM EDTA (pH 9.0) in 
95% (v/v) formamide. Products were separated using 18% (w/v) polyacrylamide gel 
electrophoresis and visualized using a Typhoon imaging system (GE Healthcare).  
LC-MS Primer Extension Assays. A 14-mer oligomer (FAM-5´-GGTGGTCCATAA(dU)C-
3´) was annealed to the 19-mer oligomers as described above. Full-length primer extension was 
performed with 2.5 μM oligonucleotide complex in 50 mM Tris-HCl buffer (pH 7.5) containing 50 
mM NaCl, 5 mM MgCl2, 1 mM dNTPs, 2% (v/v) glycerol, 50 μg/mL BSA, and 5 μM hPol η at 37 
°C for 1 h. The reactions were stopped by spin column filtration to remove the salts and buffer 
before redissolving in UDG stock buffer (1 mM DTT and 1 mM EDTA in 20 mM Tris-HCl, pH 8.0) 
and treating with 25 units of UDG for 37 °C for 4 h, then adding 0.25 M piperdine and heating at 
95 °C for 1 h. To examine reaction products, samples were analyzed by LC-MS/MS, performed 
with a Waters Acquity UPLC system (Waters, Milford, MA) interfaced to a Thermo-Finnigan LTQ 
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mass spectrometer (Thermo Scientific Corp., San Jose, CA) equipped with an ESI source. 
Chromatographic separation was achieved using a Waters Acquity UPLC BEH octadecylsilane 
(C18) column (1.0 mm ´ 10 mm, 1.7 μm) at a flow rate of 0.3 mL/min. Mobile Phase A consisted 
of 10 mM NH4CH3CO2, and Mobile Phase B was 10 mM NH4CH3CO2 in 95% CH3CN in H2O (v/v). 
The gradient started at 2% B, increased to 10% B at 5 min, 30% B at 9 min, and was held there 
for 2 min before returned to 2% B for 2 minutes (all v/v). The column was maintained at 50 °C. 
The MS conditions were as follows:  capillary temperature, 350 °C; source voltage, 4kV; source 
current, 100 μA; capillary voltage, -35 V; tube lens voltage, -93 V. MS fragmentation analysis was 
performed using data dependent scanning with a collision energy of 35%, m/z isolation width of 
2, activation Q of 0.25, and an activation time of 30 ms. Product ion spectra were taken over an 
m/z range of 300-2000, and the most abundant species (-2 charge) was used for collision-induced 
dissociation (CID). 
2.2.3 Protein Expression 
2.2.3.1 SPRTN  
 SPRTN was expressed and purified as described as previously reported (110). The 
SPRTN gene construct was assembled by Genscript, containing the full length SPRTN-WT 
codon-optimized for bacterial expression, an N-terminal Hisx6- and Z-basic- tag, and a C-terminal 
Hisx6-tag. The gene was inserted into pNIC-ZB expression vector, and 5 μL of the vector was 
transformed into BL21 ArcticExpress (DE3) competent E. coli cells. The transformed cells were 
plated on lysogeny broth (LB) agar plates supplemented with 50 μg/mL kanamycin to generate 
bacterial colonies. Isolated colonies were selected and subjected to sequence analysis to confirm 
the incorporation of the SPRTN gene and used to inoculate 100 mL of LB medium containing 
kanamycin (50 μg/mL) that was incubated at 37 °C with shaking at 250 rpm overnight. Expression 
cultures were grown by adding 10 mL of the overnight culture into 1 L of Terrific Broth medium 
containing kanamycin, and the protein was expressed by inducing the expression vector with 0.5 
μM IPTG at 20 °C for 18 h. The expression culture was centrifuged at 5000 x g for 10 min to pellet 
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the bacteria. The supernatant was removed, and the bacterial pellet was resuspended in 250 mL 
of 100 mM HEPES buffer (pH 7.4) containing 500 mM NaCl, 1 mM MgCl2, 10 mM imidazole, 10% 
glycerol (v/v), 1 mM DTT, 0.1% Triton X-100 (v/v), and a protease inhibitor mixture (cOmplete™, 
EDTA-free, Roche Applied Science). The cells were lysed by sonication until the solution was 
homologous, and 1 unit of Benzonase® was added to the cell lysate. The lysate was centrifuged 
to remove the cellular debris at 35,000 x g for 30 min. The supernatant was collected and loaded 
onto a 5-mL nickel-nitrilotriacetic acid (Ni-NTA) FPLC column (HisTrap HP, GE Healthcare) that 
has been equipped with both Buffer A (100 mM HEPES (pH 7.4) containing 500 mM NaCl, 10 
mM imidazole, 10% glycerol (v/v), and 1 mM DTT) and Buffer B (100 mM HEPES (pH 7.4) 
containing 500 mM NaCl, 300 mM imidazole, 10% glycerol (v/v), and 1 mM DTT) and kept at 4 
°C. The column was equilibrated with 7% of Buffer B at a flow rate of 0.5 mL/min prior to loading 
the protein. The bound protein was washed with two column volumes of 20% Buffer B before 
performing a linear gradient to 100% Buffer B over 10 column volumes (Figure A.4). The purified 
enzyme was then dialyzed against 100-fold volumes of 20 mM HEPES (pH 7.4) containing 500 
mM NaCl and 10% glycerol (v/v). The Z-basic tag was removed from the protein by treating with 
50 units of TEV protease at 4 °C for 72 h. The protein was then concentrated using a centrifugal 
filter with a 3 kDa molecular weight cut-off filter (Amicon® Ultra 4, Millipore Sigma) to a volume of 
~500 μL. This solution was then loaded onto a size-exclusion column (Superdex 75 10/300, GE 
Healthcare) using FPLC to further purify the protein away from the TEV protease and the cleaved 
Z-basic tag. The column was equilibrated with 20 mM HEPES buffer (pH 7.4) containing 500 mM 
NaCl and 10% glycerol (v/v) and the protein was eluted with a flow rate of 0.5 mL/min (Figure 
A.5). The protein purity was confirmed by SDS-PAGE, and the sample was frozen at -80 °C in 
small aliquots until use.  
2.2.3.2 AGT 
 Recombinant human AGT with a C-terminal Hisx6 tag was expressed in E. coli and 
purified by metal affinity chromatography using a protocol adapted from a previous report (93). 
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Briefly, an E. coli codon-optimized cDNA corresponding to the sequence reported by Pegg and 
associates (121) of the human wild type protein was transformed into XL-1 Blue cells and plated 
on LB agar containing 100 μg/mL ampicillin. Isolated colonies were used to inoculate overnight 
cultures consisting of 100 mL LB medium containing 100 μg/mL ampicillin, shaking at 250 rpm at 
37 °C for 12-15 h. Four-liter flasks containing 1 L of Terrific Broth medium containing ampicillin 
were inoculated with 10 mL aliquots of the overnight culture and incubated at 37 °C for ~4 h until 
reaching an OD600 of ~0.6. Expression of the protein was induced by supplementing the cultures 
with 0.3 mM IPTG and incubated at 37 °C for 24 h with shaking at 220 rpm. The expression culture 
was centrifuged at 5000 x g for 10 min to pellet the bacteria. The supernatant was removed, and 
the bacterial pellet was resuspended in 250 mL of 20 mM Tris-HCl buffer (pH 7.4) containing 500 
mM NaCl, 5 mM imidazole, 5% glycerol (v/v), 1 mM DTT, 0.1% Triton X-100 (v/v), and a protease 
inhibitor mixture (cOmplete™, EDTA-free, Roche Applied Science). The cells were lysed by 
sonication until the solution was homologous. The lysate was centrifuged to remove the cellular 
debris at 35,000 x g for 30 min. The supernatant was collected and loaded onto a 1-mL nickel-
nitrilotriacetic acid (Ni-NTA) FPLC column (HisTrap HP, GE Healthcare) that had been 
equilibrated with both Buffer A (20 mM Tris-HCl (pH 7.4) containing 500 mM NaCl, 5 mM 
imidazole, 5% glycerol (v/v), and 1 mM DTT) and Buffer B (20 mM Tris-HCl (pH 7.4) containing 
500 mM NaCl, 100 mM imidazole, 5% glycerol (v/v), and 1 mM DTT) and kept at 4 °C. The column 
was equilibrated with 7% Buffer B at 0.5 mL/min prior to loading the protein. The bound protein 
was washed with two column volumes of 20% Buffer B before performing a linear gradient to 
100% Buffer B over 10 column volumes. The purified enzyme was then dialyzed against 100-fold 
volumes of 20 mM Tris-HCl (pH 7.4) containing 500 mM NaCl and 5% glycerol (v/v) prior to storing 
at -80 °C. 
2.2.4 SPRTN Assays  
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A custom DNA oligonucleotide was designed for SPRTN protease activity assays (Figure 
A.3). The oligonucleotide was 50 nucleotides in length with a G:C content of 50%. Both ss- and 
ds-DNA were used in these assays.  
2.2.4.1 SPRTN Protease Assays 
Protease activity assays were performed with 1-6 μM SPRTN using 10 μM DNA as a 
modulator. Assays were performed either with other proteins (10 μM) or with SPRTN alone. 
Incubations were done in the presence of 25 mM Tris-HCl buffer (pH 7.4) containing 200 μM 
ZnCl2. Incubations were performed with ss-DNA, ds-DNA, or no DNA. The reactions were done 
at 37 °C for up to 24 h prior to quenching 12 μL aliquots using 4 μL of NuPAGE™ LDS Sample 
Buffer (ThermoFisher Scientific) and heating to 95 °C for 5 min. Samples were loaded onto a 
denaturing SDS protein gel to resolve the reaction products using a 4-12% gradient gel and 2-(N-
morpholino)ethanesulfonic acid (MES) buffer (pH 7.3). The proteins were separated at 150 V for 
1 h before removing the gel and imaging using either Coomassie SimplyBlue™ or SYPRO™ 
Ruby Protein Gel Stains (ThermoFisher Scientific).  
2.2.4.2 AGT-crosslink Degradation 
 AGT-DNA crosslinks were formed by incubating 20 μM DNA with 15 μM recombinant AGT 
and 10 mM DBE in 500 μL of 50 mM potassium phosphate buffer (pH 7.6) at 37 °C for 3 h. The 
excess DBE was removed by running the sample through a 3 kDa molecular weight cut-off filter 
(Amicon® Ultra 4, Millipore Sigma) and washing with excess amounts of 50 mM potassium 
phosphate buffer (pH 7.6). The reaction products were analyzed by SDS-PAGE to confirm the 
presence of a DPC. The crosslink was further incubated with 2 μM SPRTN to degrade the AGT 
protein crosslinks over a period of 24 h to monitor the degradation of the DPC band. Samples of 
the reaction mixture (25 μL) were removed at selected time points and treated at 55 °C for 5 min 
to heat inactivate SPRTN. The reaction was first monitored by loading 5 μL (from each timepoint) 
on a 4-12% denaturing protein gel and imaging using SYBR Safe™ (ThermoFisher Scientific) to 
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image the DNA and Coomassie SimplyBlue™ (ThermoFisher Scientific) to image the protein 
bands.  
The remaining 20 μL from each sample was used for proteomic analysis, which was first 
reduced using 10 mM DTT at 37 °C for 30 min. The samples were then treated with 25 mM 
iodoacetamide and incubated in the dark on a shaker at room temperature for 30 min to alkylate 
all free thiols. The samples were further blocked by the addition of 20 mM DTT at 37 °C for 10 
min. The samples were then split into two even aliquots. The first aliquot was used to purify the 
DNA from the sample using Fe3+-IMAC columns. This was first diluted into 300 μL of 0.1 M acetic 
acid and then loaded onto Fe3+-IMAC columns conditioned using PHOS-Select™ Fe3+ chelate 
matrix (Sigma Aldrich) in SigmaPrep™ Spin Columns (Sigma Aldrich). The columns were 
incubated for 30 min with mixing to bind the DNA to the matrix. After incubation, the columns were 
centrifuged at 8,200 x g for 30 s to remove unbound peptides/proteins. The columns were washed 
with 500 μL of 250 mM acetic acid with 30% CH3CN (v/v) and 500 μL H2O with centrifugation prior 
to adding 500 μL of 250 mM NH4OH. The columns were incubated for 5 min, with shaking, prior 
to eluting the DNA from the columns by centrifugation for 1 min. Both groups of aliquots were then 
dried using vacuum centrifugation prior to suspending in 48% hydrofluoric acid (v/v) and 
incubating at 4 °C for 16 h. The samples were dried under a stream of nitrogen and resuspended 
twice in 50 μL of CH3OH before drying again. The samples were redissolved in 20 μL of 0.1% 
HCO2H in H2O (v/v) and submitted for proteomic analysis.  
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CHAPTER 3† 
 
Formation and Bypass of S-[2-(N6-Deoxyadenosinyl)ethyl]glutathione in DNA by 
Translesion DNA Polymerases 
3.1 Introduction 
 Halogenated hydrocarbons are widely used in commerce and industry, e.g. as solvents, 
pesticides, and propellants. 1,2-Dibromoethane (DBE, ethylene dibromide) has been historically 
used as an anti-knock additive in fuel and also has had uses as a pesticide in soil and in the 
organic synthesis of various compounds such as vinyl bromide. DBE is a known carcinogen 
(122,123) and had the highest hazard score for carcinogens in the Human Exposure/Rodent 
Potency Index prior to changes in the restrictions on the compound (76). DBE causes tumors in 
rats and mice in several different tissues, including nasal cavity, blood vessels, skin, lung, kidney, 
and liver (77-80).  
 DBE is not particularly reactive itself. It can be oxidized to 2-bromoacetaldehyde, but there 
is considerable evidence that the more important reaction in genotoxicity is conjugation with GSH, 
facilitated by GSH transferases (88,124-127). The resulting product S-(2-bromoethyl)GSH, a half-
mustard, then reacts with DNA through an episulfonium ion intermediate (Figure 3.7) (89,90). S-
(2-Chloroethyl)GSH can be synthesized and used as a substitute, generating the same products 
(120,128). Multiple DNA adducts arising from the GSH-DBE conjugate include those formed at 
the N7, N2, and O6 positions of 2´-deoxyguanosine (dG) as well as the N1 position of 2´-
deoxyadenosine (dA) (99,129). Mutations of a transgene in mouse liver were attenuated by an 
inhibitor of GSH synthesis, indicating that these adducts strongly contribute to DBE genotoxicity 
in vivo (130).  
† This chapter was adapted from Sedgeman, C. A., Su, Y., and Guengerich, F. P. (2017) 
Formation of S-[2-(N6-Deoxyadenosinyl)ethyl]glutathione in DNA and Replication Past the 
Adduct by Translesion DNA Polymerases. Chem. Res. Toxicol. 30, 1188-1196. 
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 A similar chemical mechanism is involved in the DBE modification of the DNA repair 
protein O6-alkylguanine DNA alkyltransferase (AGT, MGMT) (93,131-134) and other proteins that 
become crosslinked to DNA (94,95). After calf thymus DNA was treated with DBE in the presence 
of AGT, we identified adducts at the N7, N1, N2, and O6 positions of dG (92,134) and an N6-dA 
adduct, which had not been seen in the earlier work with GSH. This adduct was reported at levels 
similar to those of the other non-labile adducts (the N7-dG adduct is labile and can depurinate) 
(92,134).  
 In this work, we investigated the ability of DBE, and more specifically the GSH conjugate 
S-(2-chloroethyl)GSH [an analogue of S-(2-bromooethyl)GSH, with similar biological properties 
(120,128)] to react at the N6 position of deoxyadenosine to form S-[2-(N6-
deoxyadenosinyl)ethyl]GSH in calf thymus DNA. Extension studies were performed in duplex 
oligonucleotides containing the adduct by human translesion synthesis DNA polymerases (hPols) 
h, i, and k and with S. solfataricus DNA polymerase Dpo4, E. coli polymerase I Klenow fragment, 
and bacteriophage T7 polymerase.  
 
3.2 Results 
3.2.1 Synthesis of S-[2-(N6-Deoxyadenosinyl)ethyl]GSH and an Oligonucleotide Containing the 
Lesion  
S-[2-(N6-Deoxyadenosinyl)ethyl]GSH was synthesized as a standard to quantitate the adduct in 
calf thymus DNA and characterized by positive ESI-MS/MS (Figure 3.2) and 1H-NMR (Figure A.1). 
Additionally, an 19-mer oligonucleotide containing S-[2-(N6- deoxyadenosinyl)ethyl]GSH was 
prepared for in vitro replication assays (Figure 3.1). 
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Figure 3.1 LC-MS Characterization of the S-[2-(N6-deoxyadenosinyl)ethyl]GSH-containing 
Oligonucleotide. UPLC chromatogram (A), mass spectrum of product at 6.35 min (B), and 
deconvoluted mass spectrum of product (C). 
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GSH was treated with N-BOC-protected 2-bromoethylamine and deprotected to release 
the free amino group. The product was used for coupling with 6-chloropurine, either for the 
synthesis of a free nucleoside or a 19-mer oligonucleotide for the standard and replication studies, 
respectively. In the reaction, the amino group from 2-aminoethyl GSH displaced the 6-chloro 
group, resulting in the formation of dA with a thioethylene linkage to GSH. The site of attachment 
at the dA N6 atom is at the Cys-ethylamino nitrogen and not the Glu α-amino group, as revealed 
by the M-129 plus M-116 losses in the mass spectra; the former is indicative of a GSH adduct 
(Figure 3.1) (135). This is the same result seen with the synthesis of the N2-dG adduct previously, 
established in a different way (136).  
The S-[2-(N6-deoxyadenosinyl)ethyl]GSH standard was purified by HPLC and 
characterized by positive ESI-MS. The oligonucleotide containing S-[2-(N6-
deoxyadenosinyl)ethyl]GSH was purified by gel electrophoresis and characterized by negative 
ESI-MS (Figure 3.2).  
3.2.2 Formation of S-[2-(N6-Deoxyadenosinyl)ethyl]GSH in DNA 
Calf thymus DNA was treated with S-(2-chloroethyl)GSH at 37 °C for 30 min. The DNA 
was then extracted, digested with nucleases and alkaline phosphatase, and desalted prior to LC-
MS analysis. A peak corresponding to the correct retention time and mass of the adduct and 
fragmenting to m/z 340 (loss of γ-glutamine plus loss of deoxyribose) was observed in the 
chromatogram (Figure 3.2A and C). Similar fragmentation patterns for the parent ion were found 
in both the standard and the reaction product (Figure 3.2B and D). The levels of the adduct were 
quantified in relation using the standard. Using a concentration of 250 mM S-(2-chloroethyl)GSH 
for the reaction, 2.5 S-[2-(N6-deoxyadenosinyl)ethyl]GSH adducts/104 bases were detected. 
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Figure 3.2 Detection of S-[2-(N6-Deoxyadenosinyl)ethyl]GSH in Calf Thymus DNA treated with 
S-(2-choroethyl)GSH. UPLC chromatogram of synthetic S-[2-(N6-deoxyadenosinyl)ethyl]GSH (A) 
and reaction product (C), observing precursor ion m/z 585 fragmenting to m/z 340. MS/MS data 
of precursor ion m/z 585 splitting into fragment ions for synthetic standard (tR 8.19 min) (B) and 
reaction product (tR 8.21 min) (D). 
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3.2.3 Primer Extension Assays 
To investigate the ability of DNA polymerases to bypass the S-[2-(N6-
deoxyadenosinyl)ethyl]GSH adduct, FAM-labeled primer extension assays were performed in 
duplex oligonucleotide substrates containing the site-specifically incorporated S-[2-(N6-
deoxyadenosinyl)ethyl]GSH adduct in the template strand. Replication experiments were done 
with the human translesion polymerases hPol κ, η, and ι, as well as with S. solfataricus Dpo4, 
bacteriophage Pol T7, and E. coli DNA polymerase I Klenow fragment. 
To determine the replication bypass of the GSH adduct, primer extension assays were 
performed in the presence of all four dNTPs (Figures 3.3 and 3.4). hPol η, Dpo4, and Klenow 
fragment were the most efficient of the four polymerases in terms of producing full-length primer 
products (P+7). hPol ι showed slight bypass of the adduct (P+2) but required higher enzyme 
concentrations (40 nM) and longer reaction incubations for extended bypass. However, hPol κ 
and Pol T7 were strongly blocked by the adduct. These polymerases were able to insert the two 
bases prior to the adduct site, but only low levels of bypass were observed after a 60 min 
incubation at 37 °C. Overall, the S-[2-(N6-deoxyadenosinyl)ethyl]GSH adduct considerably 
blocked replication by each of the three human DNA polymerases. 
Primer extension assays were also performed in the presence of single dNTPs to study 
misincorporation opposite the GSH adduct (Figure 3.5). hPol κ incorporated the correct dTTP in 
the control oligonucleotide but was completely blocked by the adduct. hPols η and ι each had 
similar or lower extents of misincorporation opposite the DNA adduct compared to the control 
template. Interestingly, Dpo4 showed less misincorporation opposite the S-[2-(N6-
deoxyadenosinyl)ethyl]GSH adduct compared to the control template. 
To better understand the catalytic efficiency of the incorporation of each dNTP and the 
frequency of misinsertion, steady-state kinetic analysis was performed with hPols κ, η, and ι 
(Table 3.1). Compared to the unmodified substrate with dA, the S-[2-(N6-
deoxyadenosinyl)ethyl]GSH adduct decreased the catalytic efficiency of correct dTTP  
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Figure 3.3 Primer Extension by DNA Polymerases in the Presence of All Four dNTPs. (A) Primer 
and template sequences where X is dA or S-[2-(N6-deoxyadenosinyl)ethyl]GSH (N6-dA-ethyl-
GSH). Reactions were done with FAM-labeled primer in the presence of hPol κ (B), hPol η (C), 
hPol ι (D), and Dpo4 (E). Reactions were conducted for increasing times (indicated in minutes) in 
the presence of 20 nM enzyme with the exception of hPol ι (40 nM). 
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Figure 3.4 Additional Primer Extension by DNA Polymerases in the Presence of All Four dNTPs. 
(A) Primer and template sequences where X is dA or S-[2-(N6-deoxyadenosinyl)ethyl]GSH (N6-
dA-ethyl-GSH). Reactions were done with FAM-labeled primer in the presence of bacteriophage 
T7 DNA polymerase (117) (B) or Klenow fragment (118) (C) at 20 nM for the indicated times (in 
min, at 37 °C). 
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Figure 3.5 Primer Extension in the Presence of Single dNTPs by Y-family DNA Polymerases. (A) 
Primer and template sequences where X is dA or S-[2-(N6-deoxyadenosinyl)ethyl]GSH (N6-dA-
ethyl-GSH). Reactions were done with FAM-labeled primers in the presence of hPol κ (B), hPol η 
(C), hPol ι (D), and Dpo4 (E). Reactions were conducted for 5 minutes in the presence of 20 nM 
enzyme with the exception of hPol ι (40 nM). 
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Table 3.1 Steady-State Kinetic Analysis of DNA Primer Single-Base Insertion Reaction 
polymerase template dNTP kcat (min-1) Km (µM)    kcat/Km (min-1 
µM-1) 
fa 
hPol κ dA T 5.0 ± 0.4 25 ± 7 0.20 1 
  A 0.013 ± 0.002 170 ± 62 0.000079 0.00040 
 N6-dA-ethyl-GSH T 0.044 ± 0.014 230 ± 140 0.00019 1 
  A n/ab n/ab n/ab n/a 
hPol η dA T 0.59 ± 0.02 0.67 ± 0.12 0.89 1 
  A 0.49 ± 0.03 21 ± 5 0.023 0.026 
  C 0.88 ± 0.07 91 ± 18 0.0097 0.011 
  G 0.49 ± 0.04 20 ± 5 0.025 0.028 
 N6-dA-ethyl-GSH T 0.89 ± 0.07 5.6 ± 1.2 0.16 1 
  A 1.6 ± 0.2 120 ± 28 0.013 0.083 
  C 0.89 ± 0.03 92 ± 7 0.0096 0.060 
  G 0.12 ± 0.01 4.9 ± 1.0 0.024 0.15 
hPol ι dA T 2.3 ± 0.2 33 ± 8 0.069 1 
  A 0.076 ± 0.004 79 ± 10 0.00096 0.014 
 N6-dA-ethyl-GSH T 1.9 ± 0.1 42 ± 9 0.046 1 
  A 0.062 ± 0.003 36 ± 5 0.0017 0.038 
 
a Misinsertion frequency f = [kcat/Km]incorrect / [kcat/Km]correct  
  b DNA incorporation was below limits of quantitation (kcat < 0.004 min-1) 
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incorporation by each of the polymerases. hPol κ was strongly hindered by the adduct, with the 
catalytic efficiency for correct incorporation decreased >103-fold, while hPol η (5.6-fold) and pol ι 
(1.5-fold) had less attenuation. The catalytic efficiency of misincorporation was also low for the 
various polymerases. With hPol η, there was an increase in misinsertion frequency of dATP, 
dCTP, and dGTP of 3.2-, 5.5-, and 5.4-fold, respectively. The misinsertion frequency of dATP was 
also increased with hPol ι (2.7-fold) while the misinsertion of dATP by hPol κ was below the limit 
of quantitation (kcat < 0.004 min-1).  
3.2.4 Primer Extension Analysis by LC-MS  
While steady-state kinetic measurements provide useful information about the catalytic 
efficiency of the correct versus incorrect incorporation opposite the DNA adduct, this analysis 
does not provide any information about the patterns of extension nor other types of mistakes such 
as frame-shift events. Therefore, full primer extension assays were performed, in the presence of 
all four dNTPs, using LC-MS/MS analysis to sequence nucleotide incorporations opposite and 
after the S-[2-(N6-deoxyadenosinyl)ethyl]GSH adduct. This analysis utilizes a uracil-containing 
primer (5´-GGTGGTCCATAA(dU)C-3´), and the product is cleaved using UDG followed by hot 
piperdine treatment to create a shorter DNA oligonucleotide for MS analysis (114,137). Analysis 
was performed with hPol η because its minsertion frequencies were the highest of the three DNA 
polymerases. The product species were isolated and fragmented using CID (Figure 3.6). These 
fragment ions were then compared to theoretical ions calculated using an Oligo Mass Calculator 
(The RNA Institute, University of Albany SUNY, Albany, NY; 
http://mods.rna.albany.edu/masspec/Mongo-Oligo) to identify the products. Analysis of the 
unmodified oligonucleotide showed only the correct full-length replication product, whereas the 
modified oligonucleotide revealed an n-1 frameshift (3%) and a dCTP misinsertion opposite the 
adduct (6%) in the full-length replication product (Table 3.2).  
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Figure 3.6 DNA Replication Sequencing by LC-MS/MS. Extracted ion chromatograms and 
MS/MS spectra of ions at m/z 947.3 (-2) (A and C) and 939.2 (-2) (B and D) from full-length primer 
extension products formed by hPol η in the presence of all four dNTPs.  
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Table 3.2 LC-MS/MS Analysis of DNA Primer Extension  
5´6FAM-GGTGGTCCATAAUC      
    3´-CCACCAGGTATTTGXCTCT    
      
product sequence m/z (-2) peak area 
% 
frameshift 
%C %T 
CTGAGA 947.1 60842       
CTGAGAA 1103.3 125955     91 
CCGAGA 939.6 13057   6   
C_GAGA 795.0 5746 3     
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3.3 Discussion 
Mutagenic DNA-peptide crosslinks can be formed from DBE with the tripeptide GSH and 
the DNA repair protein AGT (138). We first reported a crosslink formed with GSH following the 
reaction of GSH and DBE with DNA in the presence of GSH transferase (89). The major adduct 
was identified at the N7 position of dG (89,139,140) with lesser amounts of adduction located at 
the N2 and O6 positions of dG (99) as well as the N1 position of dA (129). Our studies on the 
sites of adduction of AGT later identified the N6 position of dA as another adduction site that had 
not been seen using GSH (92). Therefore, we were interested in whether or not the GSH adduct 
was also formed at the N6 position of dA and, if so, what its biological properties are. 
S-[2-(N6-Deoxyadenosinyl)ethyl]GSH was detected in calf thymus DNA treated with S-(2-
chloroethyl)GSH (Figure 3.2). Higher concentrations of S-(2-chloroethyl)GSH were used for DNA 
modification compared to our previous studies, which may explain why the adduct was not 
detected previously. However, the result can also be explained by advances in analytical 
chemistry, particularly in mass spectrometry, since 1992. Adjusting the concentration of S-(2-
chloroethyl)GSH used to that in our earlier work would predict the extent of modification for the 
S-[2-(N6-deoxyadenosinyl)ethyl]GSH adduct to be ~0.1% of the total adducts (Figure 3.7). The 
levels of the N6-dA adduct formed with GSH are in the range of those formed at the dG N2 and O6 
and the dA N1 positions (99). We had previously reported that S-[2-(N1-
deoxyadenosinyl)ethyl]GSH did not convert to S-[2-(N6-deoxyadenosinyl)ethyl]GSH in a Dimroth 
rearrangement unless the sample was subjected to high pH (129).  
Replication studies were done with the S-[2-(N6-deoxyadenosinyl)ethyl]GSH adduct 
placed in a 19-mer oligonucleotide, utilizing a sequence that has been used previously in this 
laboratory for GSH crosslinking studies (141). Qualitative analysis of the bypass efficiency of 
various translesion polymerases (Figure 3.3) showed that Dpo4 was the most efficient 
polymerase for replicating past the adduct, followed by hPol η and hPol ι. hPol κ was strongly  
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Figure 3.7 Structures and Relative Quantities of Glutathione-DNA Crosslinks Formed from 
Dibromoethane (99). S-[2-(N6-deoxyadenosinyl)ethyl]GSH is shown in bold. dR: 2´-deoxyribose.  
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blocked by S-[2-(N6-deoxyadenosinyl)ethyl]GSH, showing no replication past the adduct. These 
results were similar to previous studies showing hPol η to be the most efficient for bypass of bulky 
adducts in the major groove of DNA (46,142,143). Dpo4, although sometimes considered to be a 
homolog of hPol κ, had similar activity as hPol η (144).   
In single-base insertion assays, dTTP was the nucleoside triphosphate most readily 
incorporated opposite the adduct (Figure 3.5). Steady-state kinetic analysis showed that 
misincorporation was somewhat higher than in controls for hPol η and hPol ι, with less than a five-
fold increase in misinsertion frequency for the dNTPs (Table 3.1). This increase was similar to our 
previous results with hPol η and hPol ι with the S-[4-(N6-deoxyadenosinyl)-2,3-
dihydroxylbutyl]GSH adduct (141). hPol κ was severely blocked by the adduct, and no 
misincorporation was detected opposite the adduct in the work with hPol κ.  
In order to better understand the insertion events opposite and past the adduct, LC-
MS/MS analysis was performed to sequence the synthesized extension product. This protocol 
(114) utilizes an uracil residue in the primer strand, which allows the extension product to be cut 
using UDG/piperdine. Following cleavage, the products can be analyzed by HPLC-ESI-MS/MS, 
identified, and quantified. This experiment was performed only with hPol η, due to its high level of 
misinsertion of each of the dNTPs (Table 3.2). The major products formed included the correct 
base T inserted opposite the S-[2-(N6-deoxyadenosinyl)ethyl]GSH with or without a blunt-end 
addition. A minor product corresponding to 6% of the overall product represented a misinsertion 
of C opposite the adduct, approximately the same percentage as the misinsertion predicted by 
steady-state kinetic analysis. An additional product was a -1 frameshift deletion, accounting for 
3% of the product. The -1 frameshift product corresponds to the addition of a G opposite the C 5´ 
to the adduct and is consistent with the preferential insertion of G in the steady-state kinetic 
analyses (Table 1), in which a frameshift would not have been detected. Apparently if A is inserted 
(Table 1), it is not extended to generate full-length product. 
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Other N6-adenyl adducts are known in the literature. The role of N6-methyldeoxyadenosine 
is well-established in epigenetic mechanisms but to my knowledge no information is available 
regarding miscoding. Treatment of DNA with classical small alkylating agents does not yield much 
in the way of N6-alkyl dA products (145). An adduct was found to be formed from endogenous N-
nitroso compounds to generate the lesion N6-carboxymethyl-2´-deoxyadenosine (146). However, 
this lesion did not block DNA replication or induce mutations in vitro or in E. coli (147,148). 
However, some larger electrophiles do generate N6-dA DNA adducts (149), including some 
polycyclic hydrocarbons and aryl amines, which have been studied in some detail (150,151). In 
work from our group discussed earlier (141), the N6-adenyl adduct formed by conjugation of 
butadiene diepoxide (and hydrolysis), the DNA polymerases studied here (η, ι, κ, Dpo4) were not 
very affected, but this entity linked to GSH caused hPol κ to insert C. Studies with two other 
butadiene-related adducts showed that N6-(2-hydroxy-3-buten-1-yl)2’-deoxyadenosine retarded 
polymerization but did not affect fidelity, but one isomer of N6,N6-(2,3-hydroxybutan-1,4-diyl)-2´-
deoxyadenosine caused lack of selectivity in nucleotide incorporation with hPols η and κ (152). 
The adduct N6-oxopropenyl 2´-deoxyadenosine retarded the human translesion synthesis DNA 
polymerases but did not lead to error-prone polymerization (153). 
One open question is how misincorporation at N6-[2-[deoxyadenosinyl]ethyl]GSH 
compares with the other DBE-GSH adducts we have characterized (Figure 3.7). Three of these 
(the corresponding N7-, N2-, and O6-dG adducts) had been synthesized earlier in this laboratory 
(136) but had only been examined with two E. coli DNA polymerases, pol I (Kenow fragment) and 
pol II exo¯ (154). (The human translesion synthesis DNA polymerases were yet unknown, and 
we do not currently have these three modified oligonucleotides in hand.) However, all three of the 
adducts showed some blockage and miscoding with E. coli Pol I and Pol II (154). We are still 
interested in establishing the relative abilities of the different adducts to retard polymerization and 
miscode with the human DNA polymerases, as well as their functions in human cells. 
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In conclusion, we identified the S-[2-(N6-deoxyadenosinyl)ethyl]GSH adduct formed in 
calf thymus DNA. hPols η and ι, S. solfataricus Dpo4, and E. coli Pol I Klenow fragment were 
capable of bypassing the adduct without significant obstruction. The incorporation proceeds with 
relatively low but definite misincorporation by hPols η and ι and S. solfataricus Dpo4. These 
results help elucidate the relevance of individual GSH-coupled adducts in relation to the overall 
mutagenic effects of DBE. 
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CHAPTER 4 
 
Degradation and Bypass of DNA-Protein Crosslinks formed by AGT at the N6-
Position of Adenosine 
4.1 Introduction  
The genomes of cellular organisms are under constant stress from endogenous and 
exogenous stress (74). This stress can result in the numerous types of DNA damage, including 
oxidative damage, alkylation, base mismatches, bulky lesions, intrastrand and interstand DNA 
crosslinks, and DNA-protein crosslinks. One under-examined class of DNA lesion is DNA-protein 
crosslinks (DPCs). This class of DNA lesions is formed by the covalent attachment of a protein to 
the nucleobase, sugar, or phosphodiester moiety of a DNA molecule. This type of DNA lesion can 
be detrimental due to its large size, which prohibits DNA replication and RNA transcription from 
ensuing. An example is DPCs formed from O6-alkylguanine DNA alkyltransferase (AGT) (93). 
There are a few notable endogenous causes of DPCs. Topoisomerases cause DPCs during their 
enzymatic mechanism to unwind DNA (96-98). DNA polymerase b also can form DPCs with 
abasic sites while excising it from a DNA strand (155). DPCs can be formed via exogenous 
crosslinking agents as well, such as UV light, ionizing radiation, certain transition state metals, 
platinum-based chemotherapeutics (cisplatin), and various carcinogens such as formaldehyde.  
Little is known about the mechanisms for repair of DPC lesions, with the exception of 
DPCs produced with topoisomerases. After proteolysis of the topoisomerase to small peptide 
fragments, the repair protein tyrosyl-DNA phosphodiesterase-1 or -2 (TDP1 and TDP2) 
hydrolyzes the phosphotyrosyl bond between the protein and DNA (96,98). For all other types of 
DPCs, it is thought that they are repaired either through DNA degradation and recombination or 
nucleotide-excision repair (NER). Nuclease dependent repair of DPCs utilizes the MRN complex 
to cleave the DNA on both sides of the protein crosslink, forming a double-stranded break in the 
DNA (156,157). The DNA can then be further processed by the canonical mechanisms of DNA 
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double-stranded break repair, homologous recombination, or non-homologous end joining. The 
other pathway for repair of DPCs involves NER, which cleaves the DNA on both sides of the 
adduct to remove the damaged strand DNA. DNA polymerases utilize the complimentary strand 
of DNA to resynthesize the excised portion to complete the repair of DNA. As well, it has been 
widely postulated that translesion DNA polymerases could bypass DPCs when encountered 
during DNA replication. While this mechanism tends to be more error-prone, it is less complex 
compared to either of the aforementioned repair pathways and would prevent stalled replication 
forks. However, if either NER or TLS occur, larger proteins (>10 kDa) would block these pathways 
from proceeding (100,101). These DPCs would require a nuclear protease to degrade the protein 
to a smaller size that would allow either pathway to ensue. 
Recent research has discovered a yeast protease, Wss1, that can perform this 
degradation of DPCs (102). A human homologue, SPRTN, was found to have the same activity 
(110,112). The name, SPRTN, is derived from the putative zinc metalloprotease domain SprT 
located in the N-terminal part of the protein but the enzyme was first portrayed as a facilitator for 
p97 binding in regulating DNA damage response (103,104). The protease activity of SPRTN was 
later characterized as a zinc-dependent metalloprotease that is only active in the presence of 
DNA. It has the ability to degrade itself and other DNA-binding proteins such as topoisomerases, 
histones, and Rad5 but had no activity on non-DNA binding proteins (110,112,113).  
The available literature suggests that SPRTN may be the protease required for TLS to 
occur past DPCs found during DNA replication. The purpose of this project was to determine if 
SPRTN can cleave DPCs formed from AGT. We synthesized an oligonucleotide that contains an 
AGT crosslink at the N6-position of adenosine in a DNA primer-template complex. The DPC was 
reacted with SPRTN to allow degradation of the protein before testing bypass of the DPC by the 
human DNA polymerase h.  
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4.2 Results 
4.2.1 Synthesis of S-[2-(N6-Deoxyadenosinyl)ethyl]AGT Peptide-Containing Oligonucleotides 
 DNA oligonucleotides were synthesized with synthetic peptides from the active site of AGT 
to model potential bypass substrates for Y-family DNA polymerases. Three different peptide 
adducts were synthesized: a tripeptide (PCH, 3mer), heptapeptide (LIPCHRV, 7mer), and a 
decapentepeptide (PVPILIPCHRVVSSS, 15mer). The 15-mer peptide was altered at its 13th 
position, where in the wild-type human protein there is another cysteine. To prevent multiple 
reactable thiol groups, this residue was altered into a serine residue. These peptides were 
purchased with the N-terminus protected with an acetyl group and the C-terminus protected with 
an amide group to prevent reactions from occurring at the termini. To crosslink the peptides to 
the DNA, the peptides were first treated with MSH to selectively convert the cysteines into 
dehydroalanines.  
The 19-mer DNA oligonucleotide containing a 6-chloropurine was reacted with cystamine 
to form an adenosine with the cystamine linked to the N6-position. The disulfide on the cystamine 
was then reduced to form the aminoethylthiol. The modified DNA oligonucleotide was then 
incubated with the peptides to react through a Michael addition to form the DNA-peptide crosslink 
with an ethyl linkage. The oligonucleotides were purified by HPLC and their identities were 
confirmed by LC-MS.  
4.2.2 Bypass of AGT Peptide Crosslinks 
The ability of Y-family DNA polymerases to bypass DNA-peptide crosslinks was assessed 
by performing in vitro bypass assays. The replication assays were performed with duplex DNA 
with a FAM-labeled primer using hPol κ, η, and ι, as well as with S. solfataricus Dpo4 as the 
translesion DNA polymerases. 
Full-length primer extension assays were first performed to study the ability for the 
enzymes to bypass the DNA-peptide crosslinks (Figure 4.1). These assays were performed in the   
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Figure 4.1 Primer Extension Assays in the Presence of All Four dNTPs by Y-Family DNA 
Polymerases. (A) Primer and template sequences where X is dA or N6-dA-ethylene-15mer 
peptide from the active site of AGT. Reactions were done with FAM-labeled primers in the 
presence of hPol κ (B), hPol ι (C), hPol η (D), and Dpo4 (E). Reactions were conducted over a 
time course from 0-40 minutes in the presence of 20 nM enzyme with the exception of hPol ι (40 
nM).  
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presence of all four dNTPs and tested the ability of the polymerases to incorporate the two bases 
prior to the crosslink, opposite the adduct, and to complete the replication to the end of the DNA 
template. In order to test the ability of the polymerases to bypass bulky peptide crosslinks, these 
assays were performed using the 15-mer peptide crosslink (Figure 4.1). hPol η and Dpo4 were 
the most efficient of the enzymes to bypass the peptide crosslink. However, hPol κ was strongly 
blocked by the adduct. These polymerases were able to insert the two bases prior to the adduct 
site, but no detectable levels of bypass were observed after a 40-minute incubation at 37 °C. hPol 
ι also showed no bypass of the adduct (P+2) even using higher enzyme concentrations (40 nM), 
but only slight extension of the control template was detected after 40 min.  
 To understand the misincorporation of the DNA polymerases opposite the peptide 
crosslinks, primer extension assays in the presence of individual dNTPs were performed (Figure 
4.2). These assays were performed with a 14-mer DNA primer to allow the first nucleotide 
incorporation to be inserted opposite the DNA-peptide crosslink. Similar to the earlier assay, hPol 
κ was blocked by each of the peptide crosslinks on the DNA compared to the control template. It 
was able to incorporate small amounts of dTTP for each of the 3-, 7-, and 15-mer peptide 
crosslinks, and interestingly, hPol κ appeared to have increased ability to incorporate dTTP 
opposite the 15-mer peptide crosslink compared to the shorter crosslinks. hPol ι had similar levels 
of incorporation opposite the 3-mer and 7-mer peptide crosslinks as its control template, showing 
almost full incorporation of dTTP with slight misincorporation of dATP followed by dCTP and 
dGTP. The 15-mer peptide crosslink caused a decrease in each of the incorporations by hPol ι in 
while causing the polymerase to have a similar level of misincorporation as the smaller peptide 
crosslinks. hPol η was able to perform multiple incorporations by each of the dNTPs opposite the 
control template. It was able to insert multiple dNTPs opposite each of the peptide crosslinks as 
well, but the levels of the incorporation decreased as the peptide crosslink length increased. Dpo4 
also inserted multiple nucleotides opposite the control template for each of dATP, dCTP, and   
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Figure 4.2 Primer Extension in the Presence of Individual dNTPs by Y-Family DNA Polymerases. 
(A) Primer and template sequences where X is dA or N6-dA-ethylene-peptides from the active site 
of AGT. Peptides used were 3, 7, and 15 amino acids in length. Reactions were done with FAM-
labeled primers in the presence of hPol κ (B), hPol ι (C), hPol η (D), and Dpo4 (E). Reactions 
were conducted for 5 minutes in the presence of 20 nM enzyme with the exception of hPol ι (40 
nM). Work done by Dr. K. Johnson. 
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Table 4.1 Steady-State Kinetic Analysis of DNA Primer Single-Base Insertion Reaction by hPol 
η. 
Template dNTP kcat (min-1) Km (µM)    kcat/Km (min-1 
µM-1) 
fa 
dA T 1.6 ± 0.1 0.87 ± 0.15 1.8 1 
 A 0.79 ± 0.03 20 ± 3 0.040 0.022 
 C 0.50 ± 0.03 83 ± 15 0.0060 0.0033 
 G 0.26 ± 0.01 9.8 ± 1.7 0.027 0.015 
N6-Adenyl-peptide T 0.33 ± 0.03 8.1 ± 2.2 0.041 1 
 A 0.13 ± 0.01 240 ± 50 0.00054 0.013 
 C 0.093 ± 0.007 92 ± 18 0.0010 0.024 
 G 0.037 ± 0.003 28 ± 8 0.0013 0.032 
  
a Misinsertion frequency f = [kcat/Km]incorrect / [kcat/Km]correct  
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dTTP, with minor incorporation of dGTP. Opposite the 3-mer and 7-mer peptide, Dpo4 completely 
incorporated dTTP with minor levels of misincorporation of dATP and dCTP. However, it was 
partially blocked when incorporating dTTP opposite the 15-mer peptide crosslink and had 
increased levels of misincorporation of dCTP compared to the smaller peptide crosslinks.  
 Based on this evidence, as well as previously published work (141,158), hPol η was 
utilized to test the catalytic efficiency for the incorporation opposite the 15-mer peptide-DNA 
crosslink due to its ability to bypass peptide crosslinks at the N6 position of adenosine. Steady-
state kinetic analysis was performed using the 15-mer peptide crosslink to have a better 
understanding of the misincorporation levels by the polymerase (Table 4.1). hPol η had a 
significant decline in the catalytic efficiency for the correct incorporation opposite the 15-mer 
peptide crosslink compared to the control template, decreasing 44-fold. The misincorporation 
levels for the bypass of the crosslink were similar to the levels for the control template, showing 
slight increases for dCTP (0.33% to 2.4%) and dGTP (1.5% to 3.2%). 
4.2.3 Degradation of AGT by SPRTN 
 Recombinant wt-SPRTN was expressed and purified in an E. coli protein expression 
system. The protein construct was designed based on a previously reported construct (110), 
containing an N-terminal Hisx6- plus Z-basic tag and a C-terminal Hisx6 tag. The gene construct 
for the recombinant protein was transformed into BL21 ArcticExpress (DE3) cells before 
expressing the protein at 20 °C for 18 h. The protein was purified by FPLC using a Ni-NTA column 
before removal of the N-terminal tag and further purification by size-exclusion chromatography. 
The identity of the protein was confirmed western blot and purity of the protein was checked by 
SDS-PAGE using a total protein stain. SPRTN was also shown to be active by self-digestion 
assays (Figure A.6).  
To address the ability of SPRTN to degrade AGT-DNA crosslinks, protease assays were 
first performed with free AGT and SPRTN to determine if SPRTN has protease activity with AGT.  
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Figure 4.3 Proteolytic Degradation of AGT by SPRTN. AGT was incubated in the presence of 
either single-stranded DNA (red) or double-stranded DNA (blue) over a 24 hour time course with 
SPRTN. Incubations were performed in duplicate. Error bars denote standard deviation 
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Figure 4.4 Proteomic Analysis of AGT Degradation by SPRTN. The black underline denotes the 
peptide that was present in all three timepoints. The additional peptides underlined in red were 
present only after a 16 h incubation with SPRTN. The position of the crosslinked DNA is marked 
by the green star. 
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SPRTN and AGT were incubated in the presence of both dsDNA or ssDNA (Figure 4.3). The 
reactions were done over a time course to 24 h to monitor the digestion of the AGT over time. 
SPRTN degraded the AGT in both dsDNA and ssDNA to similar levels and was found to degrade 
most of the protein by 24 h.  
 An AGT-DNA crosslink was then synthesized to observe the ability of SPRTN to degrade 
the crosslink. AGT was incubated with dibromoethane (DBE and the 50-mer duplex DNA to form 
the an AGT crosslink on DNA. Gel analysis identified that the crosslink was formed on DNA. 
SPRTN was then incubated with the DPC over a period of 16 h to complete digestion of the AGT 
protein. Proteomic analysis of the degraded AGT yielded peptides originating from the N-terminus 
of the protein. SPRTN cleaved AGT at three different sites, between an aspartic acid and serine, 
a leucine and serine, and a glycine and cysteine. Only one peptide, MDKDCEMKRTTLD, was 
able to be identified at the 2 and 4 h timepoints, but at the 16 h timepoint there were four different 
peptides identified including the peptide found earlier. The new peptides were formed from 
cleavages further into the AGT protein compared to the first peptide. 
4.2.4 Synthesis, Degradation, and Bypass of a Site Specific AGT-DNA Crosslink 
 To determine if hPol η can bypass the digested AGT peptide-DNA crosslink, a site specific 
AGT crosslink was formed on a primer-template DNA duplex. The chemical synthesis scheme 
used for the peptide crosslinks from the active site of AGT was attempted, but the yield of the 
reaction was extremely low when attempted with the full AGT protein. Therefore, a second 
chemical synthesis scheme was developed to synthesize the protein crosslink using click 
chemistry. Using the same 6-chloropurine-containing oligonucleotide, the DNA was treated with 
propargyl amine to create an alkyne linker on the N6 position of adenosine. This was then 
annealed to a 12-mer DNA primer before undergoing the copper-catalyzed azide-alkyne 
cycloaddition using an azide with an iodoacetamide linker. With the linker attached, the DNA 
duplex was incubated with AGT to form the crosslink at the active site cysteine (C145) of the   
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Figure 4.5 Formation of AGT-DNA Protein Crosslink. (A) SDS-PAGE analysis showing the 
formation of the N6-dA-AGT crosslink, showing formation of the crosslink after 4 hours (lane 2) 
and 24 h (lane 3) compared to an AGT standard (lane 4). (B) LC-MS/MS analysis confirming the 
identity of the AGT crosslink at the active site cysteine residue of AGT.  Work done by Dr. P. 
Ghodke.
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Figure 4.6 Bypass of AGT Protein Crosslinked to DNA. AGT-DNA crosslink was incubated with 
(right) or without (left) with SPRTN for 48 h to degrade the protein. Full primer extension was then 
performed by the addition of hPol η. Reactions were conducted for varying amounts of time 
(indicated in minutes) in the presence of 20 nM enzyme.  
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protein. Gel and proteomic analysis both confirmed the formation of the AGT crosslink on the 
DNA duplex (Figure 4.4). The crosslink was then purified by FPLC to remove all free DNA from 
the sample using Ni2+-IMAC to elute the bound protein (Figure A.7). Due to tight binding of free 
DNA to AGT, 1.5 M NaCl was used to weaken the interaction between the two as well as a long 
wash step prior to elution of the crosslink. 
 The AGT-DNA crosslink was then incubated with SPRTN for 48 h to degrade the crosslink. 
The SPRTN reaction product, as well as the AGT-DNA crosslink, were incubated with hPol η in 
the presence of all four dNTPs to allow full primer extension of the adduct (Figure 4.5). The AGT-
DNA crosslink caused the polymerase to stall after two nucleotide incorporations (P+2), signifying 
that the protein blocked the replication of the template at the site of the crosslink, as well as a 
minor band near the top of the gel showing full extension of the DNA primer. This minor product 
is assumed to be the result of contaminating free DNA as shown by evidence by 32P labeling 
(Figure A.8). After treatment with SPRTN the P+2 band disappeared, and full extension of the 
primer strand was observed.  
 
4.3 Discussion 
DNA-protein crosslinks have been a recent focus in the field of DNA damage and repair 
for the interest in the deleterious effects that they may cause as well as the recent discovery of 
the nuclear protease, SPRTN, that can degrade them. Although protein crosslinks formed by 
proteins such as GADPH and histones did not cause any negative effects to cells (94,95), there 
has been overwhelming data showing AGT crosslinks to DNA are both highly cytotoxic and 
mutagenic to both bacterial and mammalian cells (93,131,159). This has led to significant interest 
in determining the mechanism of these effects of DPCs formed by AGT. While previous research 
has observed the ability of SPRTN to degrade nuclear proteins, our studies are the first to actually 
involve the degradation of a DPC, specifically the crosslinks formed by AGT. We observed the 
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results of a DPC forming at the N6 position of adenosine and elucidated the effects that the 
crosslink in respect to SPRTN digestion and replication post-proteolysis.  
Site-specific DNA crosslinks were first synthesized with synthetic peptides derived from 
the active site of AGT. Three peptides of increasing size (3 to 15 aa) were used for the synthesis 
to simulate the peptides to remain after proteolytic decay in cells. The peptides were centered 
around the active site cysteine which was determined to be the site of adduction when forming 
the crosslinks. These peptides were crosslinked using a novel synthetic chemistry scheme 
resulting in their conjugation onto the N6 position of adenosine with an ethyl linkage, mimicking 
the same linkage that was found to be deleterious in cells.  
Replication assays were performed with the peptide crosslinks on a 19-mer DNA 
oligonucleotide used previously in the laboratory (141,158). Qualitative analysis of the bypass 
ability of various translesion DNA polymerases showed that hPol h was the most efficient to fully 
bypass the 15-mer peptide crosslink (Figure 4.1). Dpo4 also was able to efficiently bypass the 
lesion, but was found to stall after the fourth nucleotide incorporation. Neither hPol ι nor hPol κ 
were found to be able to bypass the crosslink, showing stalling at both the P+1 and P+2 positions. 
These results were consistent with previous studies that hPol h was the major polymerase 
capable of bypassing bulky major groove adducts (46,142,143). Showing that hPol h is capable 
of bypassing the 15-mer peptide crosslink, we deemed it unnecessary to perform full-bypass 
assays using the smaller peptide crosslinks. 
Single-base insertions were performed with each of the peptide crosslinks to get an 
understanding of the misincorporation for each of the translesion DNA polymerases (Figure 4.2). 
Consistent with the primer assay using all four dNTPs, hPol κ was significantly blocked by each 
of the peptide crosslinks and was only able to perform minor incorporation of the correct dTTP. 
hPol ι was able to efficiently incorporate dTTP opposite the 3- and 7-mer peptide crosslinks with 
minor misincorporation of dATP, but its total incorporation decreased in the presence of the 15-
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mer peptide crosslink. High levels of incorporation were detected using hPol η in the presence 
with each of the dNTPs, most likely due to the high dNTP concentration and reaction duration 
used for this experiment. To gain a better understanding of the role of hPol η to perform 
misinsertions, steady-state kinetic analysis was completed using the 15-mer peptide crosslink 
(Table 4.1). This analysis determined the catalytic efficiency for hPol η to incorporate dTTP 
opposite the crosslink decreased 45-fold compared to the undamaged control template. The 
misincorporation for the enzyme was only slightly higher for the crosslink compared to the control, 
increasing from approximately 4% to 7% for all of the dNTPs.  
Following the discovery of SPRTN in late 2016, we moved forward in expressing and 
purified the protease to test its ability to degrade AGT. SPRTN was first tested with unbound AGT 
to get a grasp on the rate of degradation of the protein. We found that SPRTN degraded AGT to 
~20% of its total level within a 24 h incubation with either single- or double-stranded DNA. From 
here we synthesized AGT-DNA crosslinks using dsDNA and DBE and monitored the proteolysis 
of the AGT crosslink. Proteomic analysis was performed to determine the locations of cleavage 
on AGT by SPRTN. Preliminary results showed cleavage of AGT on the N-terminus of the protein, 
with the first peptide appearing within 2 h of the SPRTN incubation and further peptides being 
detected at 16 h. The proteolytic activity of SPRTN at the N-terminus of AGT was identical to 
previously reported degradation of histones at the N-terminus by SPRTN (110).  
To fully understand the ability of SPRTN to degrade AGT-DNA crosslinks, we synthesized 
a site-specific AGT crosslink on a DNA primer-template duplex. Initial attempts to synthesize the 
crosslink using peptide synthesis scheme proved to be unsuccessful at resulting in detectable 
levels of the protein crosslink. To obtain useable amounts of the protein crosslink, a new synthesis 
scheme was designed utilizing click chemistry to attach an iodoacetamide linker to the DNA 
(Figure 4.5). This group selectively reacted with the cysteine 145 of the protein, resulting in the 
AGT crosslink, albeit with a longer linker than formed through environmentally. Purifying  
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Figure 4.7 Computational Modeling of DPC Fitting into the Active Site of Human Polymerase η. 
Structure of the polymerase is shown in white, based on PDB file 5DG9. The DNA duplex is shown 
in the active site of the enzyme, showing the template strand in yellow and the primer strand in 
blue. The incoming dTTP (green) is shown lining up opposite the adenosine with the click-reaction 
linker (pink) adducted at the N6-position of the adenosine. The 15-mer peptide (red) can be 
situated outside of the enzyme active site. Modeling was done in collaboration with Dr. Pradeep 
Pallan.  
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the protein crosslink proved to be equally, if not more, challenging to remove the unmodified DNA 
from the sample. Multiple attempts using affinity columns to separate the crosslink from 
unmodified DNA proved unsuccessful. A primer extension assay in the presence of all four dNTPs 
using hPol η did show that the protein blocked the majority of the extension prior to the crosslink 
(P+3), but a minor band was detected showing full primer extension (Figure 4.6). 32P assays were 
utilized to confirm the presence of unmodified template DNA in the sample used for the replication 
(Figure A.8), leading us to believe that the full extension of the primer was due to the unmodified 
DNA as the large size of AGT would prevent the activity of the polymerase. However, after 
treatment of the AGT-DNA crosslink with SPRTN the stalled bands disappeared on the gel, 
showing the ability of the degradation of the AGT crosslink to allow replication bypass to occur. 
Molecular modeling experiments were also performed to test if hPol η would be able to 
accommodate AGT in its active site. Using the crystal structure of hPol η performing replication, 
we modeled in the linker used for the protein crosslink. The entire protein was not able to fit in 
with the DNA without having steric clashing with hPol η. Modeling in the 15-mer peptide with the 
click chemistry linker was able to fit however, showing the peptide sitting in a cleft outside of the 
protein away from the DNA (Figure 4.7).  
Our results show that SPRTN is capable of degrading DPCs formed with AGT. The 
degradation of this protein appears to allow translesion DNA synthesis to occur by hPol η. The 
ability of hPol η to perform this replication is not surprising due previous literature showing its 
ability to bypass DNA-peptide crosslinks located in the major groove of DNA. Other research has 
found that these polymerases are capable of bypassing peptides of similar lengths as the 15-mer 
peptide described here, although the model linkers normally used are longer which may help 
accommodate the peptide outside the active site of the polymerase (143,160,161). Interestingly, 
misincorporation by hPol η was still low when bypassing the 15-mer peptide crosslink during 
replication. This would lead us to believe that the elevated mutations formed by AGT-DNA 
crosslinks must originate via another mechanism, such as by complications in the DNA repair 
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processes involved in its removal, but further experimentation would be required to determine this 
mechanism. 
In conclusion, we performed DNA replication assays opposite DNA-peptide crosslinks 
originating from the active site of AGT located at the N6 position of adenosine. Dpo4 and hPol η 
were able to bypass the largest peptide crosslink while hPols κ and ι were hindered, and the 
bypass was shown to have low levels of misincorporation. We were able to determine that SPRTN 
is capable of degrading AGT and AGT-DNA crosslinks. This degradation was then shown to 
alleviate stalled replication opposite AGT-DNA crosslinks by allowing TLS DNA replication to 
occur.  
  
  78 
CHAPTER 5 
 
Conclusions and Future Directions 
5.1 Conclusions 
 The study of DNA-protein crosslinks is complicated by the diversity of the forms in which 
they exist. DPCs can occur with all four dNTPs, some with multiple locations. The agent involved 
in generating the crosslink can be short or long as well as flexible or rigid. Proteomic analysis has 
also identified hundreds of proteins that can be crosslinked to DNA. Therefore, it is very difficult 
to characterize exactly what role DPCs have in the field of DNA damage because each crosslink 
can be different.  
Little effort has been put into trying to characterize the effects of DPCs in cells. Our lab 
has investigated the effects of four proteins using bis-electrophiles as the crosslinking agent. 
Perplexingly, we found that two, AGT and GSH, had cytotoxic and mutagenic effects while the 
other two, GADPH and histone H2b, had no effects (94,95). These results lead us to believe that 
either there are multiple pathways by which DPCs are handled or that some proteins are 
inherently detrimental when crosslinked. My dissertation has focused on the elucidation of the 
mechanism for how DPCs formed using either GSH or AGT are mutagenic. To investigate this, 
the effects of crosslinks at the N6 position of adenosine were synthesized and tested for 
misincorporation during replication by various translesion DNA polymerases. Degradation assays 
were also performed on the AGT protein crosslink to investigate the necessity of a nuclear 
protease to allow for bypass of the protein crosslink. 
 Chapter III describes the role of the S-[2-(N6-deoxyadenosinyl)ethyl]glutathione in DNA. 
This lesion was previously not known to exist in DNA, presumably because previous detection 
limits were not low enough to detect the adduct. S-[2-(N6-Deoxyadenosinyl)ethyl]glutathione was 
proposed to exist after the N6 adenosine adduct was detected using AGT as the crosslinked 
protein. Detection of this adduct was identified by reacting GSH and calf thymus DNA. The 
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reaction product was degraded using a mixture of nucleases to degrade the DNA prior to 
quantitation by LC-MS and comparison to a synthetic standard. Its level of formation was found 
to be similar to those of the other non-labile adducts. A site-specific GSH crosslink was 
synthesized with N6-dA to perform replication assays by treating GSH with N-(BOC)-protected 2-
bromoethylamine. After deprotection of the modified GSH, it was incubated with a 6-chloropurine-
containing oligonucleotide to synthesize the lesion. Replication assays showed that hPol η was 
the major polymerase capable of bypassing the lesion. The misincorporation levels opposite hPol 
η were modestly higher, from 1-3% to 6-15% for each of the dNTPs. Sequencing the extension 
products by mass spectrometry revealed similar levels of misincorporation, but an interesting 
discovery was the presence of frameshift mutations in the extension products. This type of 
mutation is vastly more detrimental to the cell compared to substitution reactions due to its 
potential to alter the codon frames during transcription and would help clarify the severity the 
genotoxic effects of the GSH crosslinks (130).  
My results have helped shed light on the total number of adduction sites for GSH-DNA 
crosslinks. While it was suspected for years that the N6-dA crosslink exists, these are the first 
results confirming that hypothesis. The levels of the N6-dA crosslink were similar as compared to 
the other sites of adduction when normalizing for the amount of GSH and dibromoethane used to 
synthesize the crosslink. Studying the ability of TLS polymerases to bypass this crosslink was 
also quite important in order to determine the mechanism for how DPCs are mutagenic. GSH-
DNA crosslinks were known to be mutagenic from mouse experiments (130), but there was no 
direct analysis to determine what mutations were formed or the roles for each of the DNA adducts 
formed by dibromoethane and GSH crosslinks to cause mutations. The results presented in 
Chapter III demonstrate that these mutations can directly come from translesion DNA synthesis 
as compared to DNA repair of the lesion or other potential mechanisms. A previous paper studying 
N6-dA GSH crosslinks using butadiene diexpoxide found that the misincorporation by hPol η was 
lower as compared to the results shown in Chapter III but did find high misincorporation levels by 
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hPol κ (141). The logical explanation for the differences in the hPol κ rates would be that the 
presence of the longer linker allowed its activity as compared to the shorter linker, but the earlier 
work also used higher DNA concentrations as compared to the work reported here (5 μM 
compared to 120 nM).  
 Chapter IV describes the effects of AGT-DNA crosslinks at the N6 position of adenosine. 
The goal of this project was to determine if a nuclear protease is capable of degrading AGT-DNA 
crosslinks to allow DNA replication to progress, and subsequently, if this replication was error-
prone. The first solution to this question was through the chemical synthesis of synthetic peptides 
from the active site of AGT attached to adenosine at the N6 position. This strategy would elucidate 
the ability of the translesion polymerases, notably hPol η, to bypass potential degradation 
products. As predicted, hPol η was capable of bypassing the synthetic peptide crosslinks, 
although its catalytic efficiency decreased 45-fold compared to the control template. Surprisingly 
however, the misincorporation levels by hPol η opposite the crosslink were quite similar as 
compared to the control template. With the discovery of SPRTN as a nuclear protease, an effort 
to determine its ability to degrade AGT and AGT-DNA crosslinks was pursued. Expression of 
SPRTN was obtained by developing a gene construct based on a previously reported manuscript 
(110). The protein was designed to contain an N-terminal Z-basic plus a Hisx6 tag, as well as a 
C-terminal Hisx6 tag. The gene was inserted into a pNIC-ZB expression vector and transformed 
into E. coli designed for low temperature expression. The protein was expressed at 20 °C and 
purified using metal affinity chromatography prior to size exclusion chromatography. SPRTN was 
found to be active both in the presence of double-stranded DNA and single-stranded DNA, both 
for the proteolytic degradation of itself and other proteins. It was found that SPRTN can cleave 
AGT as well as AGT-DNA crosslinks. In proteomic analysis, the only peptides that were located 
were at the N-terminus of the protein and far from the active site (cysteine-145). In order to 
establish if SPRTN could degrade AGT-crosslinks to allow for TLS to occur, a site-specific AGT-
DNA crosslink was synthesized and treated with SPRTN prior to reaction with hPol η to analyze 
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replication bypass. Initial steps to synthesize the crosslink using the same synthesis scheme as 
the peptide crosslinks proved unsuccessful. A more robust system—using click chemistry and 
iodoacetamide to link AGT to DNA—was found to be successful, albeit with low yields (~10%). 
Techniques for purifying this crosslink by binding the protein by its His tag proved rather difficult, 
in that AGT was capable of binding DNA throughout the elution phase on column 
chromatography. The AGT crosslink was treated with SPRTN, and the AGT crosslink (before and 
after SPRTN treatment) was incubated with hPol η in full extension assays. The AGT-DNA 
crosslink predominantly blocked replication by hPol η, but a minor band was detected 
representing full extension of the primer. This extension, however, is believed to be the result of 
contaminating free DNA in the sample, as shown by 32P labeling of the DNA template. Treatment 
with SPRTN prior to replication resulted in the loss of the dominant band representing blocked 
replication, indicating that proteolytic degradation of the AGT-DNA crosslink allows TLS to occur.   
The mechanism of how AGT crosslinks are cytotoxic and mutagenic is still not completely 
known. Increased cell death can be explained by the lack of repair and ability of replication 
machinery to bypass the lesion, stalling DNA replication/transcription and thus destabilizing the 
cell to trigger cell death pathways. Increased DNA mutation is less clear, in that multiple 
mechanisms could explain the phenomenon. While the results of the kinetic analysis of hPol η did 
not show a substantial rise in the mutation frequency opposite the 15mer peptide crosslink, this 
analysis was only done on misincorporation of one of five adducts formed by AGT (92). The N7-
dG adduct is the most abundant of all of AGT crosslinks, but its role is less certain due to the 
lability of the adduct to hydrolyze to produce an abasic site. However, based on the 
misincorporation frequency with abasic sites by TLS pols, one would expect to incorporation of 
dA opposite the abasic site. The other lesions on guanine (the N1, N2, and O6) positions have yet 
to be studied regarding misincorporation frequency. Based on the location of the N2-dG lesion in 
the minor groove of DNA, it should be susceptible to bypass by hPol κ instead of hPol h, and 
there may be a different result compared to what was found with the N6-dA adduct.  
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An alternative hypothesis would be that the mutations arise from complications during 
DNA repair, notably occurring during DNA replication. Complex DNA repair pathways involving 
homologous recombination or nonhomologous end-joining could be the cause for these mutations 
due to the complexity of double strand DNA breaks. However, these complex pathways would 
not be likely to form the base pair mutations observed with ethylene dibromide (93,131-133). 
Other repair by pathways such as nucleotide excision repair would require proteolytic degradation 
by a nuclear protease such as SPRTN prior to being able to access the DNA for repair. During 
DNA replication, this process could be cumbersome and require an extended period of time to 
sufficiently degrade the protein. AGT may be unique in its complexion or size after SPRTN 
degradation and still render the cell unable to be repaired by NER, causing a longer delay before 
the cell switches to an alternative pathway for repair. Either of these events could result in a 
lengthy stalled replication forks, causing additional damage to occur on the surrounding DNA and 
resulting in DNA mutations. Another possibility is that AGT is unique in that SPRTN is unable to 
digest AGT crosslinks on DNA, but the results from Chapter IV show that SPRTN is capable of 
degrading AGT, at least in vitro.  
During the work on this dissertation, multiple strategies for the chemical synthesis and 
purification of DNA crosslinks to either peptides or proteins have been attempted. The initial 
strategy, performed in Chapter III, utilized a simple nucleophilic substitution reaction to react a 
thiol with an alkyl halide containing a terminal amine. This substituted peptide would then react 
with the oligonucleotide containing the 6-chloropurine nucleobase to form the crosslink, 
performing another nucleophilic substitution reaction of the free amine with the chlorine. This 
strategy worked well using the peptide GSH, but attempts using the longer peptides from the 
active site of AGT proved difficult in that the alkyl halide also reacted with histidine residues. The 
second strategy for the AGT peptides (Chapter IV) used MSH to convert the thiol of the peptide 
to a dehydroalanine. The DNA oligonucleotide containing the 6-chloropurine was reacted with 
cystamine to perform a nucleophilic substitution reaction, as described above prior to reduction 
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and reaction with the dehydroalanine-containing peptide. The yield of this reaction was lower 
compared to the first reaction but proved to be specific for the adduction at the cysteine residue. 
For the synthesis of the AGT-DNA crosslink, neither technique proved successful. Both alkylation 
and conversion to a dehydroalanine of the active site cysteine caused the protein to precipitate, 
preventing viable crosslink formation. The third technique, using the click chemistry linker (first 
treating the DNA with propargyl amine and subsequent addition of the iodoacetamide to the 
linker), was successful in the reaction with the protein, although with low (~10%) yields.  
Several different approaches were also used for purification of the crosslinks. The GSH 
crosslink was purified by gel electrophoresis because attempts with HPLC proved unsuccessful 
from separating the crosslinked DNA from the starting material. The AGT peptide crosslinks were 
purified using an HPLC protocol with a gradient of aqueous 100 mM triethylammonium acetate 
(pH 7.6) to 100 mM triethylammonium acetate (pH 7.6) in acetonitrile to separate the 
oligonucleotide-peptide crosslinks, resulting in better yields compared to gel recovery.  
 
5.2 Future Directions 
 Difficulties in the synthesis and purification of the site-specific AGT-DNA crosslink have 
been challenging. All purification techniques tested to separate the crosslink from free DNA have 
been shown to be insufficient to completely remove all unreacted DNA and have also been 
plagued by the constant loss of product during purification steps. This lack of removal of free 
oligonucleotide has caused problems when trying to determine the effect of the proteolytic 
degradation of AGT by SPRTN to allow translesion synthesis past the protein crosslink. Proteomic 
analysis of the AGT peptides bound to DNA after this degradation has also proved to be difficult. 
Part of this problem has been in the recovery of peptides. Presently, it is unclear if SPRTN cleaves 
proteins by cleaving nonspecifically at the ends of the protein as opposed to the middle. If the 
cleavage products are short peptides or single amino acids, proteomic analysis could prove 
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troublesome for detecting peptides. As well, nonspecific cleavage products could cause 
inconsistent results for a specific size or identity for the remaining peptide.  
 Studying the effects of protein and peptide crosslinks at the N6 position of adenosine have 
been useful in determining how mutations arise from these crosslinks. With the availability of the 
2-fluoroinosine oligonucleotide, studying the role of crosslinked peptides at this position would 
also be useful in studying the misincorporation by both GSH and AGT peptide crosslinks. Due to 
the position of N2 in the minor groove of DNA compared the N6 in the major groove, it would be of 
interest to determine if there is a different effect. It is assumed that hPol κ would play a more 
dominant role in the bypass of these crosslinks, and a comparison of the misincorporation rates 
of hPol κ and hPol h would be valuable. Studying the effects of these crosslinks at the N1 and O6 
positions of guanine would also be of interest, but plans for their synthesis have not been 
developed yet.  
Studying the N7-dG crosslinks would also be of interest in that these are the major 
crosslinks formed with both AGT and GSH. Synthesizing site-specific crosslinks at this site may 
be feasible for study by utilizing 2′-deoxy-2′-fluoroarabinonucleic acid to stabilize the cation. 
Studying the ability of translesion DNA polymerases to bypass lesions is of great interest, not only 
of peptide crosslinks but using even the methyl adduct. Determining the bypass here would be of 
great interest, but further analysis of the stability of the N7-dG crosslinks in cells would be of 
greater interest in determining the rate of hydrolysis to abasic sites in vivo. This would be 
necessary in determining the requirement of the N7-dG crosslinks to be bypassed or repaired 
versus the cell needing to repair the increased number of abasic sites instead.  
 Another possible direction of future interest would be the study of the bypass and 
misincorporation of other proteins that are found to become crosslinked to DNA, such as GAPDH 
or histone H2b. SPRTN degradation of these proteins could be quantitated and synthetic peptides 
could be designed to mimic the bypass of peptide crosslinks at various sites on DNA. If the bypass 
of these peptides proved significantly different compared to AGT and GSH, it could lead to the 
  85 
conclusion that the detrimental effects of the AGT peptide crosslinks are sequence specific as 
compared to size or vice versa.  
 A different potential direction for this project involves the synergistic effects of the DNA 
replication machinery in bypassing DNA-peptide crosslinks. One approach would be to perform 
the in vitro replication assays for the crosslink bypass assays using multiple polymerases. This 
may be useful in determining a role for hPol ι in replicating opposite the crosslink prior to switching 
to another polymerase such as hPol κ, as shown for other DNA lesions (162). While this type of 
experiment is not very useful in quantitative analysis (e.g., steady-state kinetics), it could elucidate 
a secondary bypass mechanism for hPol ι, which has not been shown to be capable of performing 
full primer extension itself. The addition of hPol z or REV1 can also be done with these 
polymerases to elucidate their roles in extension past the crosslink. Analysis of the synergistic 
effects of the polymerases in bypass of the crosslink could, in principle, be performed in cells. 
Transfecting a plasmid containing a site-specific crosslink into mammalian cells could provide 
information on how the components of the replication machinery work together. Determining 
individual roles of the polymerases could be done by knockdown or knockout assays using siRNA 
or CRISPR-Cas9 protocols. After allowing the cells to finish replication of the transfected plasmid, 
the plasmid could be extracted and amplified in a bacterial system prior to DNA sequencing. This 
technique has been used or the analysis of mutation frequencies for various DNA lesions 
(148,163-165) and could be utilized for studying various protein crosslinks as well.  
 The discovery of SPRTN as the nuclear protease was seminal in determining the role of 
proteolytic degradation of DPCs. Because the protease is known to degrade DPCs, it can be 
determined how the proteolytic degradation of the crosslinked proteins affects repair and bypass 
of DPCs. Further experiments can be performed to determine the role of SPRTN to affect the 
cytotoxic and mutagenic effects of AGT-DNA crosslinks as seen earlier (93,131). It would be of 
interest to determine the effect of overexpression versus knockdown of SPRTN on the detrimental 
effects in cells expressing AGT and treated with dibromoethane. Further, proteomic analysis has 
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been performed to determine which proteins can form DPCs in cells (85,87). It may be of interest 
to do the analysis with and without the expression of SPRTN to determine if there are any changes 
in the relative quantitation of certain proteins detected. If one protein were to be detected at much 
higher levels in the SPRTN-expressing cells, this protein could be resistant to SPRTN degradation 
and would have the potential to have more severe effects when forming DPCs.  
 Finally, crosslinking agents such as cisplatin are commonly used in chemotherapeutic 
treatments. While this treatment is normally associated with forming DNA-DNA interstrand 
crosslinks, they will form DPCs in these patients. Known mutation of SPRTN is involved in Ruijs-
Aalfs Syndrome, and it would be interesting to know if people with this condition or other variants 
of SPRTN have different sensitivity to cisplatin and other similar chemotherapeutic agents.  
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Figure A.1 1H-NMR spectrum of S-[2-(N6-deoxyadenosinyl)ethyl]GSH standard in 2H2O (400 
MHz).  
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Figure A.2 LC-MS Characterization of the S-[2-(N6-deoxyadenosinyl)ethyl]GSH-containing 
Oligonucleotide. UPLC chromatogram (A), mass spectrum of product at 6.35 min (B), and 
deconvoluted mass spectrum of product (C).  
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5’- ATGGAACGCGCACGCCGTCCTGCATAATACTTTGAGAGAATGGCAATCCA -3’ 
3' -TACCTTGCGCGTGCGGCAGGACGTATTATGAAACTCTCTTACCGTTAGGT -5’ 
 
Figure A.3 DNA Sequence Identity for Randomized 50mer DNA Duplex. Sequence was 
generated randomly to contain a G:C content of 50%. 
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Figure A.4 First Stage Purification of SPRTN. SPRTN was initially purified using a Ni2+-NTA FPLC 
column using a gradient from 10 mM to 300 mM imidazole. Elution of the protein occurred at 150 
mL. UV absorbance was monitored at 280 nm.  
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Figure A.5 Second Stage Purification of SPRTN. After removal of the Z-basic tag from the protein, 
SPRTN was purified by size-exclusion chromatography on the FPLC using a Superdex™ 75 
10/300 column. Elution of the protein was at 9 mL. UV absorbance was monitored at 280 nm.  
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Figure A.6 Time Course for SPRTN Protease Activity. SPRTN activity was monitored for self-
degradation in the presence of dsDNA (blue), ssDNA (red), or no DNA (black). 
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Figure A.7 Purification of AGT-DNA Crosslink by FPLC. The reaction product was loaded onto 
Ni2+-NTA FPLC column and eluted using a gradient from 5 mM to 100 mM imidazole. Elution of 
the AGT crosslink was at 18 mL. UV absorbance was monitored at 280 nm. 
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Figure A.8 Detection of Unmodified DNA template in AGT-DNA Crosslink by 32P-labeling. Band 
corresponding to contaminating DNA in purified AGT-DNA crosslink (Lane 1) found at similar level 
as unmodified template DNA (Lane 2) and primer DNA (lane 3). 
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